Field of the Invention

The present invention relates to a process for producing high levels of novel truncated cellulase proteins in the filamentous fungus Trichoderma longibrachiatum: to fungal transformants produced from Trichoderma longibrachiatum by genetic engineering technigues; and to novel cellulase proteins produced by such transformants.

Background of the Invention

Cellulases are enzymes which hydrolyze cellulose (β-1,4- D-glucan linkages) and produce as primary products glucose, cellobiose, cellooligosaccharides, and the like. Cellulases are produced by a number of microorganisms and comprise several different enzyme classifications including those identified as exo-cellobiohydrolases (CBH) , endoglucanases (EG) and 3-glucosidases (BG) (Schulein, M, 1988 Methods in Enzymology 160: 235-242) . Moreover, the enzymes within these classifications can be separated into individual components. For example, the cellulase produced by the filamentous fungus, Trichoderma longibrachiatum. hereafter T.longibrachiatum. consists of at least two CBH components, i.e., CBHI and CBHII, and at least four EG components, i.e., EGI, EGII, EGIII and EGV (Saloheimo, A. et al 1993 in Proceedings of the second TRICEL symposium on Trichoderma reesei Cellulases and Other Hydrolases, Espoo, Finland, ed by P. Suominen & T. Reinikainen. Foundation for Biotechnical and Industrial Fermentation Research 8: 139-146) components, and at least one β-glucosidase. The genes encoding these components are namely cbhl. cbh2. egll. eg!2. egl3. and eg!5 respectively.

The complete cellulase system comprising CBH, EG and BG components synergistically act to convert crystalline cellulose to glucose. The two exo-cellobiohyrolases and the four presently known endoglucanases act together to hydrolyze cellulose to small cello-oligosaccharides. The

oligosaccharides (mainly cellobioses) are subsequently hydrolyzed to glucose by a major 0-glucosidase (with possible additional hydrolysis from minor β-glucosidase components) .

Protein analysis of the cellobiohydrolases (CBHI and CBHII) and major endoglucanases (EGI and EGII) of T. longibrachiatum have shown that a bifunctional organization exists in the form of a catalytic core domain and a smaller cellulose binding domain separated by a linker or flexible hinge stretch of amino acids rich in proline and hydroxyamino acids. Genes for the two cellobiohydrolases, CBHI and CBHII (Shoemaker, S et al 1983 Bio/Technology 1, 691-696, Teeri, T et al 1983, Bio/Technology 1, 696-699 and Teeri, T. et al, 1987, Gene 51, 43-52) and two major endoglucansases, EGI and EGII (Penttila, M. et al 1986, Gene 45, 253-263, Van Arsdell, J.N/ et al 1987 Bio/Technology 5, 60-64 and Saloheimo, M. et al 1988, Gene 63, 11-21) have been isolated from T. longibrachiatum and the protein domain structure has been confirmed.

A similar bifunctional organization of cellulase enzymes is found in bacterial cellulases. The cellulose binding domain (CBD) and catalytic core of Cellulomonas fimi endoglucanase A (C. fimi Cen A) has been studied extensively (Ong E. et al 1989, Trends Biotechnol. 7:239-243, Pilz et al 1990, Biochem J. 271:277-280 and Warren et al 1987, Proteins 1:335-341). Gene fragments encoding the CBD and the CBD with the linker have been cloned, expressed in E. coli and shown to possess novel activities on cellulose fibers (Gilkes, N.R. et al 1991, Microbiol Rev. 55:305-315 and Din, N et al 1991, Bio/Technology 9:1096-1099). For example, isolated CBD from C. fimi Cen A genetically expressed in E. coli disrupts the structure of cellulose fibers and releases small particles but have no detectable hydrolytic activity. CBD further possess a wide application in protein purification and enzyme immobilization. On the other hand, the catalytic domain of C. fimi Cen A isolated from protease cleaved cellulase does not disrupt the fibril structure of cellulose and instead smooths the surface of the fiber.

These novel activities have potential uses in textile, food and animal feed, detergents and the pulp and paper industries. However, for industrial application, highly efficient expression systems must be procured that produce higher yields of truncated cellulase proteins than are currently available to be of any commercial value. For example, Trichoderma longibrachiatum CBHI core domains have been separated proteolytically and purified but only milligram quantities are isolated by this biochemical procedure (Offord D., et al 1991, Applied Biochem. and Biotech. 28/29:377-386). Similar studies were done in an analysis of the core and binding domains of CBHI, CBHII, EGI and EGII isolated from T. longibrachiatum after biochemical proteolysis, however, only enough protein was recovered for structural and functional analysis (Tomme, P et al, 1988, Eur.J. Biochem 170:575-581 and Ajo, S, 1991 FEBS 291:45-49).

In order to obtain strains which express higher levels of truncated cellulase proteins than previously realized, applicants chose T. longibrachiatum as the microorganism most preferred for expression since it is well known for its capacity to secrete whole cellulases in large quantities. Thus, applicants set out to genetically engineer strains of the above filamentous fungus to express high levels of bioengineered novel protein truncated cellulases.

It remained unknown before Applicants invention whether the DNA encoding truncated cellulase binding and core domain proteins could be transformed into Trichoderma in such a manner as to overexpress novel truncated cellulase genes into functional proteins without deterioration in the host cell and obtained secretion to facilitate identification and purification of the engineered product. Recently, Nakari and Penttila have shown that it is possible to genetically engineer a Trichoderma host to express a truncated form of the Trichoderma EGI cellulase, specifically the catalytic core domain, however the level of expression of EGI core domain was low (Nakari, T. et al, Abstract Pl/63 1st European Conference on Fungal Genetics, Nottingham, England, August 20-23, 1992).

Moreover, it was unknown whether a Trichoderma cellobiohydrolase catalytic core domain or any Trichoderma cellobiohydrolase or endoglucanase cellulose binding domain could be produced by recombinant genetic methods.

Accordingly, it is an object of the present invention to introduce DNA gene fragments into strains of the fungus, Trichoderma longibrachiatum to produce transformant strains that express high levels of novel truncated protein (grams/liter level) engineered cellulases from the binding and core domains of Trichoderma cellulases. The truncated proteins are correctly processed and secreted extracellularly in an active form. The present invention further relates to the novel truncated proteins isolated from these transformants.

Summary of the Invention

Methods involving recombinant DNA technology and compositions are provided for the production and isolation of novel truncated cellulase proteins, derivatives thereof or covalently linked truncated cellulase domain derivatives derived from the filamentous fungus, Trichoderma sp. The truncated cellulase comprises at least a core or binding domain of a cellobiohydrolases or endoglucanase from the species Trichoderma. Derivatives of truncated cellulases include substitutions, deletions, or additions of one or more amino acids at various sites throughout the core or binding domain of the novel truncated cellulase whereby either the cellulose binding or cellulase catalytic core activity is retained. Covalently linked truncated cellulase domain derivatives comprise truncated cellulases or derivatives thereof that are further attached to each other, and/or enzymes, or domains and/or proteins, and/or chemicals heterologous or homologous to Trichoderma sp.

The present invention also includes the preparation of novel truncated cellulases, derivatives and covalently linked truncated cellulase domain derivatives by transforming into a host cell a DNA construct comprising a DNA fragment or variant

thereof encoding the above novel cellulase(s) functionally attached to regulatory sequences that permit the transcription and translation of the structural gene and growing the host cell to express the truncated gene of interest.

The present invention further includes DNA fragments and variants thereof encoding novel truncated cellulases, derivatives and covalently linked truncated cellulase domain derivatives. The present invention also encompasses expression vectors comprising the above DNA fragments or variants thereof and Trichoderma host cells transformed with the above expression vectors.

Brief Detailed Description of the Drawings

Figure 1 depicts the genomic DNA and amino acid sequence of CBHI derived from Trichoderma longibrachiatum. The signal sequence begins at base pair 210 and ends at base pair 260 (Seq ID No. 25) . The catalytic core domain begins at base pair 261 through base pair 671 of the first exon, base pair 739 through base pair 1434 of the second exon, and base pair 1498 through base pair 713 of the third exon (Seq ID No. 9) . The linker sequence begins at base pair 714 and ends at base pair 1785 (Seq ID No. 17) . The cellulase binding domain begins at base pair 1786 and ends at base pair 1888 (Seq ID No. 1) . Seq ID Nos. 26, 10, 18 and 2 represent the amino acid sequence of the CBHI signal sequence, catalytic core domain, linker region and binding domain, respectively.

Figure 2 depicts the genomic DNA and amino acid sequence of CBHII derived from Trichoderma longibrachiatum. The signal sequence begins at base pair 614 and ends at base pair 685 (Seq ID No. 27) . The cellulose binding domain begins at base pair 686 through base pair 707 of exon one, and base pair 755 through base pair 851 of exon two (Seq ID No. 3) . The linker sequence begins at base pair 852 and ends at base pair 980 (Seq ID No. 19) . The catalytic core begins at base pair 981 through base pair 1141 of exon two, base pair 1199 through base pair 1445 of exon three and base pair 1536 through base pair 2221 of exon four (Seq ID No. 11). Seq ID Nos. 28, 4, 20

and 12 represent the amino acid sequence of the CBHII signal sequence, binding domain, linker region and catalytic core domain, respectively.

Figure 3 depicts the genomic DNA and amino acid sequence of EGI. The signal sequence begins at base pair 113 and ends at base pair 178 (Seq ID No. 29) . The catalytic core domain begins at base pair 179 through 882 of exon one, and _β base pair 963 through base pair 1379 of the second exon (Seq ID No. 13) . The linker region begins at base pair 1380 and ends at base pair 1460 (Seq ID No. 21) . The cellulose binding domain begins at base pair 1461 and ends at base pair 1616 (Seq ID No. 5). Seq ID Nos. 30, 14, 22 and 6 represent the amino acid sequence of EGI signal sequence, catalytic core domain, linker region and binding domain, respectively.

Figure 4 depicts the genomic DNA and amino acid sequence of EGII. The signal sequence begins at base pair 262 and ends at base pair 324 (Seq ID No. 31) . The cellulose binding domain begins at base pair 325 and ends at base pair 432 (Seq ID No. 7) . The linker region begins at base pair 433 and ends at base pair 534 (Seq No. 23) . The catalytic core domain begins at base pair 535 through base pair 590 in exon one, and base pair 765 through base pair 1689 in exon two (Seq ID No. 15). Seq ID Nos. 32, 8, 24 and 16 represent the amino acid sequence of EGII signal sequence, binding domain, linker region and catalytic core domain, respectively.

Figure 5 depicts the genomic DNA and amino acid sequence of EGIII. The signal sequence begins at base pair 151 and ends at base pair 198 (Seq ID No. 36) . The catalytic core domain begins at base pair 199 through base pair 557 in exon one, base pair 613 through base pair 833 in exon two and base pair 900 through base pair 973 in exon three (Seq ID No. 33) . Seq ID Nos. 36 and 34 represent the amino acid sequence of EGIII signal sequence and catalytic core domain, respectively.

Figure 6 illustrates the construction of EGI core domain expression vector (Seq ID No. 37) .

Figure 7 depicts the construction of the expression plasmid pTEX (Seq ID Nos. 39-41) .

Figure 8 is an illustration of the construction of CBHI core domain expression vector (Seq ID No. 38) .

Figure 9 is an illustration of the construction of CBHII cellulase binding domain expression vector (Seq ID Nos. 42 and 43) .

Detailed Description

As noted above, the present invention generally relates to the cloning and expression of novel truncated cellulase proteins at high levels in the filamentous fungus, T. longibrachiatum. Further aspects of the present invention will be discussed in further detail following a definition of the terms employed herein.

The term "Trichoderma" or "Trichoderma sp." refers to any fungal strains which have previously been classified as Trichoderma or which are currently classified as Trichoderma. Preferably the species are Trichoderma longibrachiatum. Trichoderma reesei or Trichoderma viride.

The terms "cellulolytic enzymes" or "cellulase enzymes" refer to fungal exoglucanases or exocellobiohydrolases (CBH) , endoglucanses (EG) and /3-glucosidases (BG) . These three different types of cellulase enzymes act synergistically to convert crystalline cellulose to glucose. Analysis of the genes coding for CBHI, CBHII and EGI and EGII show a domain structure comprising a catalytic core region (CCD) , a hinge or linker region (used interchangeably herein) and cellulose binding region (CBD) .

The term "truncated cellulases", as used herein, refers to the core or binding domains of the cellobiohydrolases and endoglucanases, for example, EGI, EGII, EGIII, EGV, CBHI and CBHII, or derivatives of either of the truncated cellulase domains.

A "derivative" of the truncated cellulases encompasses the core or binding domains of the cellobiohydrolases, for example, CBHI or CBHII, and the endoglucanases, for example, EGI, EGII, EGIII and EGV from Trichoderma sp _f wherein there may be an addition of one or more amino acids to either or

both of the C- and N- terminal ends of the truncated cellulase, a substitution of one or more amino acids at one or more sites throughout the truncated cellulase, a deletion of one or more amino acids within or at either or both ends of the truncated cellulase protein, or an insertion of one or more amino acids at one or more sites in the truncated cellulase protein such that exoglucanase and endoglucanase activities are retained in the derivatized CBH and EG catalytic core truncated proteins and/or the cellulose binding activity is retained in the derivatized CBH and EG binding domain truncated proteins. It is also intended by the term "derivative of a truncated cellulase" to include core or binding domains of the exoglucanase or endoglucanase enzymes that have attached thereto one or more amino acids from the linker region.

A truncated cellulase protein derivative further refers to a protein substantially similar in structure and biological activity to a cellulase core or binding domain which comprises the cellulolytic enzymes found in nature, but which has been engineered to contain a modified amino acid sequence. Thus, provided that the two proteins possess a similar activity, they are considered "derivatives" as that term is used herein even if the primary structure of one protein does not possess the identical amino acid sequence to that found in the other.

The term "cellulase catalytic core domain activity" refers herein to an amino acid sequence of the truncated cellulase comprising the core domain of the cellobiohydrolases and endoglucanases, for example, EGI, EGII, EGIII, EGV, CBHI or CBHII or a derivative thereof that is capable of enzymatically cleaving a cellulosic polymers such as pulp or phosphoric acid swollen cellulose.

The activity of the truncated catalytic core proteins or derivatives thereof as defined herein may be determined by methods well known in the art. (See Wood, T.M. et al in Methods in Enzymology, Vol. 160, Editors: Wood, W.A. and Kellogg, S.T. , Academic Press, pp. 87-116, 1988) For example, such activities can be determined by hydrolysis of phosphoric

acid-swollen cellulose and/or soluble oligosaccharides followed by quantification of the reducing sugars released. In this case the soluble sugar products, released by the action of CBH or EG catalytic domains or derivatives thereof, can be detected by HPLC analysis or by use of colorimetric assays for measuring reducing sugars. It is expected that these catalytic domains or derivatives thereof will retain at least 10% of the activity exhibited by the intact enzyme when each is assayed under similar conditions and dosed based on similar amounts of catalytic domain protein.

The term "cellulose binding domain activity" refers herein to an amino acid sequence of the cellulase comprising the binding domain of cellobiohydrolases and endoglucanases, for example, EGI, EGII, CBHI or CHBII or a derivative thereof that non-covalently binds to a polysaccharide such as cellulose. It is believed that cellulose binding domains (CBDs) function independently from the catalytic core of the cellulase enzyme to attach the protein to cellulose.

The performance (or activity) of the truncated binding domain or derivatives thereof as described in the present invention may be determined by cellulose binding assays using a cellulosic substrates such as avicel, pulp or cotton, for example. It is expected that these novel truncated binding domains or derivatives thereof will retain at least 10% of the binding affinity compared to that exhibited by the intact enzyme when each is assayed under similar conditions and dosed based on similar amounts of binding domain protein. The amount of non-bound binding domain may be quantified by direct protein analysis, by chromatographic methods, or possibly by immunological methods.

Other methods well known in the art that measure cellulase catalytic and/or binding activity via the physical or chemical properties of particular treated substrates may also be suitable in the present invention. For example, for methods that measure physical properties of a treated substrate, the substrate is analyzed for modification of shape, texture, surface, or structional properties.

modification of the "wet" ability, e.g. substrates ability to absorb water, or modification of swelling. Other parameters which may determine activity include the measuring of the change in the chemical properties of treated solid substrates. For example, the diffusion properties of dyes or chemicals may be examined after treatment of solid substrate with the truncated cellulase binding protein or derivatives thereof described in the present invention. Appropriate substrates for evaluating activity include Avicel, rayon, pulp fibers, cotton or ramie fibers, paper, kraft or ground wood pulp, for example. (See also Wood, T.M. et al in "Methods in Enzymology", Vol. 160, Editors: Wood, W.A. and Kellogg, S.T., Academic Press, pp. 87-116, 1988)

The term "linker or hinge region" refers to the short peptide region that links together the two distinct functional domains of the fungal cellulases, i.e., the core domain and the binding domain. These domains in T. longibrachiatum cellulases are linked by a peptide rich in Ser Thr and Pro.

A "signal sequence" refers to any sequence of amino acids bound to the N-terminal portion of a protein which facilitates the secretion of the mature form of the protein outside of the cell. This definition of a signal sequence is a functional one. The mature form of the extracellular protein lacks the signal sequence which is cleaved off during the secretion process.

The term "variant" refers to a DNA fragment encoding the CBH or EG core or binding domain that may further contain an addition of one or more nucleotides internally or at the 5' or 3-" end of the DNA fragment, a deletion of one or more nucleotides internally or at the 5' or 3' end of the DNA fragment or a substitution of one or moere nucleotides internally or at the 5' or 3' end of the DNA fragment wherein the functional activity of the binding and core domains that encode for a truncated cellulase is retained.

A variant DNA fragment comprising the core or binding domain is further intended to indicate that a linker or hinge DNA sequence or portion thereof may be attached to the core or

binding domain DNA sequence at either the 5' or 3' end wherein the functional activity of the encoded truncated binding or core domain protein (derivative) is retained.

The term "host cell" means both the cells and protoplasts created from the cells of Trichoderma sp.

The term "DNA construct or vector" (used interchangeably herein) refers to a vector which comprises one or more DNA fragments or DNA variant fragments encoding any one of the novel truncated cellulases or derivatives described above.

The term "functionally attached to" means that a regulatory region, such as a promoter, terminator, secretion signal or enhancer region is attached to a structural gene and controls the expression of that gene.

The present invention relates to truncated cellulases, derivatives of truncated cellulases and covalently linked truncated cellulase domain derivatives that are prepared by recombinant methods by transforming into a host cell, a DNA construct comprising at least a fragment of DNA encoding a portion or all of the binding or core region of the cellobiohydrolases or endoglucanases, for example, EGI, EGII, EGIII, EGV, CBHI or CBHII functionally attached to a promoter, growing the host cell to express the truncated cellulase, derivative truncated cellulase or covalently linked truncated cellulase domain derivatives of interest and subsequently purifying the truncated cellulase, or derivative thereof to substantial homogeneity.

It is further contemplated by the present invention that one may generate novel derivatives of cellulase enzymes which, for instance, combine a core region derived from a truncated endoglucanase or exocellobiohydrolase of the present invention with a cellulose-binding domain derived from another cellulase enzyme from multiple microbial sources such as fungal and bacterial. Alternatively, it may be possible to combine a core region derived from another cellulase enzyme with a cellulose-binding domains derived from a truncated endoglucanase or exocellobiohydralase of the present invention. In a particular embodiment, the core region may be

derived from a cellulase enzyme which does not in nature comprise a cellulose-binding domain, for example, EGIII (Figure 5 and SEQ ID Nos. 33 and 34), and which is N- or C- terminally extended with a truncated cellulase or derivative thereof comprising a cellulose-binding domain described herein. In this way, it may be possible to construct novel cellulase enzymes with altered cellulose binding properties compared to natural intact cellulases.

In yet another aspect of the present invention, it is contemplated that truncated cellulases or derivatives thereof of the present invention may be further attached to each other and/or to intact proteins and/or enzymes and/or portions thereof, for example, hemicellulases, immunoglobulins, and/or binding or core domains from non Trichoderma cellulases, and/or from non-cellulase enzymes using the recombinant methods described herein to form novel covalently linked truncated cellulase domain derivatives. These covalently linked truncated cellulase domain derivatives constructed in this manner may provide even further benefits over the truncated cellulases or derivatives thereof disclosed in the present invention. It is contemplated that these covalently linked truncated cellulase domain derivatives which contain other enzymes, proteins or portions thereof may exhibit bifunctional activity and/or bifunctional binding.

In yet a further aspect, the present invention relates to a method of producing a truncated cellulase or derivative thereof which method comprises cultivating a host cell as described above under conditions such that production of the truncated cellulase or derivative thereof is effected and recovering the truncated cellulase or derivative from the cells or culture medium.

Highly enriched truncated cellulases are prepared in the present invention by genetically modifying microorganisms described in further detail below. Transformed microorganism cultures are grown to stationary phase, filtered to remove the cells and the remaining supernatant is concentrated by

ultrafiltration to obtain a truncated cellulase or a derivative thereof.

In a particular aspect of the above method, the medium used to cultivate the transformed host cells may be any medium suitable for cellulase production in Trichoderma. The truncated cellulases or derivatives thereof are recovered from the medium by conventional techniques including separations of the cells from the medium by centrifugation, or filtration, precipitation of the proteins in the supernatant or filtrate with salt, for example, ammonium sulphate, followed by chromatography procedures such as ion exchange chromatography, affinity chromatography and the like.

Alternatively, the final protein product may be isolated and purified by binding to a polysaccharide substrate or antibody matrix. The antibodies (polyclonal or monoclonal) may be raised against cellulase core or binding domain peptides, or synthetic peptides may be prepared from portions of the core domain or binding domain and used to raise polyclonal antibodies.

In a general embodiment of the present method, one or more functionally active truncated cellulases or derivatives thereof is expressed in a Trichoderma host cell transformed with a DNA vector comprising one or more DNA fragments or variant fragments encoding truncated cellulases, derivatives thereof or covalently linked truncated cellulase domain derivative proteins. The Trichoderma host cell may or may not have been previously manipulated through genetic engineering to remove any host genes that encode intact cellulases.

In a particular embodiment, truncated cellulases, derivatives thereof or covalently linked truncated cellulase domain derivatives are expressed in transformed Trichoderma cells in which genes have not been deleted therefrom. The truncated proteins listed above are recovered and separated from intact cellulases expressed simultaneously in the host cells by conventional procedures discussed above including sizing chromatography. Confirmation of expression of truncated cellulases or derivatives is determined by SDS

polyacrylamide gel electrophoresis and Western immunoblot analysis to distinguish truncated from intact cellulase proteins.

In a preferred embodiment, the present invention relates to a method for transforming a Trichoderma sp host cell that is missing one or more cellulase activities and treating the cell using recombinant DNA techniques well known in the art with one or more DNA fragments encoding a truncated cellulase, derivative thereof or covalently linked truncated cellulase domain derivatives. It is contemplated that the DNA fragment encoding a derivative truncated cellulase core or binding domain may be altered such as by deletions, insertions or substitutions within the gene to produce a variant DNA that encodes for an active truncated cellulase derivative.

It is further contemplated by the present invention that the DNA fragment or DNA variant fragment encoding the truncated cellulase or derivative may be functionally attached to a fungal promoter sequence, for example, the promoter of the cbhl or egll gene.

Also contemplated by the present invention is manipulation of the Trichoderma sp. strain via transformation such that a DNA fragment encoding a truncated cellulase or derivative thereof is inserted within the genome. It is also contemplated that more than one copy of a truncated cellulase DNA fragment or DNA variant fragment may be recombined into the strain.

A selectable marker must first be chosen so as to enable detection of the transformed fungus. Any selectable marker gene which is expressed in Trichoderma sp. can be used in the present invention so that its presence in the transformants will not materially affect the properties thereof. The selectable marker can be a gene which encodes an assayable product. The selectable marker may be a functional copy of a Trichoderma sp gene which if lacking in the host strain results in the host strain displaying an auxotrophic phenotype.

The host strains used could be derivatives of Trichoderma sp which lack or have a nonfunctional gene or genes corresponding to the selectable marker chosen. For example, if the selectable marker of pyr4 is chosen, then a specific pyr derivative strain is used as a recipient in the transformation procedure. Other examples of selectable markers that can be used in the present invention include the Trichoderma sp. genes equivalent to the Aspergillus nidulans genes argB. trpC. niaD and the like. The corresponding recipient strain must therefore be a derivative strain such as argB~. trpC ^~ . niaD ^~ . and the like.

The strain is derived from a starting host strain which is any Trichoderma sp. strain. However, it is preferable to use a T. longibrachiatum cellulase over-producing strain such as RL-P37, described by Sheir-Neiss et al. in Appl. Microbiol. Biotechnology, 20 (1984) pp. 46-53, since this strain secretes elevated amounts of cellulase enzymes. This strain is then used to produce the derivative strains used in the transformation process.

The derivative strain of Trichoderma sp. can be prepared by a number of techniques known in the art. An example is the production of pyr4~ derivative strains by subjecting the strains to fluoroorotic acid (FOA) . The pyr4 gene encodes orotidine-5'-monophosphate decarboxylase, an enzyme required for the biosynthesis of uridine. Strains with an intact pyr4 gene grow in a medium lacking uridine but are sensitive to fluoroorotic acid. It is possible to select pyr4 ^: derivative strains which lack a functional orotidine monophosphate decarboxylase enzyme and require uridine for growth by selecting for FOA resistance. Using the FOA selection technique it is also possible to obtain uridine requiring strains which lack a functional orotate pyrophosphoribosyl transferase. It is possible to transform these cells with a functional copy of the gene encoding this enzyme (Berges and Barreau, 1991, Curr. Genet. 19 pp359-365) . Since it is easy to select derivative strains using the FOA resistance

technique in the present invention, it is preferable to use the pyr4 gene as a selectable marker.

In a preferred embodiment of the present invention, Trichoderma host cell strains have been deleted of one or more cellulase genes prior to introduction of a DNA construct or plasmid containing the DNA fragment encoding the truncated cellulase protein of interest. It is preferable to express a truncated cellulase, derivative thereof or covalently linked truncated cellulase domain derivatives in a host that is missing one or more cellulase genes in order to simplify the identification and subsequent purification procedures. Any gene from Trichoderma sp. which has been cloned can be deleted such as cbhl. cbh2, egll. eg!3. and the like. The plasmid for gene deletion is selected such that unique restriction enzyme sites are present therein to enable the fragment of homologous Trichoderma sp. DNA to be removed as a single linear piece.

The desired gene that is to be deleted from the transformant is inserted into the plasmid by methods known in the art. The plasmid containing the gene to be deleted or disrupted is then cut at appropriate restriction enzyme site(s), internal to the coding region, the gene coding sequence or part thereof may be removed therefrom and the selectable marker inserted. Flanking DNA sequences from the locus of the gene to be deleted or disrupted, preferably between about 0.5 to 2.0 kb, remain on either side of the selectable marker gene.

A single DNA fragment containing the deletion construct is then isolated from the plasmid and used to transform the appropriate pyr~ Trichoderma host. Transformants are selected based on their ability to express the pyr4 gene product and thus compliment the uridine auxotrophy of the host strain. Southern blot analysis is then carried out on the resultant transformants to identify and confirm a double cross over integration event which replaces part or all of the coding region of the gene to be deleted with the pyr4 selectable markers.

Although specific plasmid vectors are described above, the present invention is not limited to the production of these vectors. Various genes can be deleted and replaced in the Trichoderma sp. strain using the above techniques. Any available selectable markers can be used, as discussed above. Potentially any Trichoderma sp. gene which has been cloned, and thus identified, can be deleted from the genome using the above-described strategy. All of these variations are included within the present invention.

The expression vector of the present invention carrying the inserted DNA fragment or variant DNA fragment encoding the truncated cellulase or derivative thereof of the present invention may be any vector which is capable of replicating autonomously in a given host organism, typically a plasmid. In preferred embodiments two types of expression vectors for obtaining expression of genes or truncations thereof are contemplated. The first contains DNA sequences in which the promoter, gene coding region, and terminator sequence all originate from the gene to be expressed. The gene truncation is obtained by deleting away the undesired DNA sequences (coding for unwanted domains) to leave the domain to be expressed under control of its own transcriptional and translational regulatory sequences. A selectable marker is also contained on the vector allowing the selection for integration into the host of multiple copies of the novel gene sequences.

For example, pEGlΔ3 ^, pyr contains the EGI cellulase core domain under the control of the EGI promoter, terminator, and signal sequences. The 3 ' end on the EGI coding region containing the cellulose binding domain has been deleted. The plasmid also contains the pyr4 gene for the purpose of selection.

The second type of expression vector is preassembled and contains sequences required for high level transcription and a selectable marker. It is contemplated that the coding region for a gene or part thereof can be inserted into this general purpose expression vector such that it is under the

transcriptional control of the expression cassettes promoter and terminator sequences.

For example, pTEX is such a general purpose expression vector. Genes or part thereof can be inserted downstream of the strong CBHI promoter. The Examples disclosed herein are included in which cellulase catalytic core and binding domains are shown to be expressed using this system.

In the vector, the DNA sequence encoding the truncated cellulase or other novel proteins of the present invention should be operably linked to transcriptional and translational sequences, i.e., a suitable promoter sequence and signal sequence in reading frame to the structural gene. The promoter may be any DNA sequence which shows transcriptional activity in the host cell and may be derived from genes encoding proteins either homologous or heterologous to the host cell. The signal peptide provides for extracellular expression of the truncated cellulase or derivatives thereof. The DNA signal sequence is preferably the signal sequence naturally associated with the truncated gene to be expressed, however the signal sequence from any cellobiohydrolases or endoglucanase is contemplated in the present invention.

The procedures used to ligate the DNA sequences coding for the truncated cellulases, derivatives thereof or other novel cellulases of the present invention with the promoter, and insertion into suitable vectors containing the necessary information for replication in the host cell are well known in the art.

The DNA vector or construct described above may be introduced in the host cell in accordance with known techniques such as transformation, transfection, microinjection, microporation, biolistic bombardment and the like.

In the preferred transformation technique, it must be taken into account that since the permeability of the cell wall in Trichoderma sp. is very low, uptake of the desired DNA sequence, gene or gene fragment is at best minimal. There are a number of methods to increase the permeability of the

Trichoderma sp. cell wall in the derivative strain (i.e., lacking a functional gene corresponding to the used selectable marker) prior to the transformation process.

The preferred method in the present invention to prepare Trichoderma sp. for transformation involves the preparation of protoplasts from fungal mycelium. The mycelium can be obtained from germinated vegetative spores. The mycelium is treated with an enzyme which digests the cell wall resulting in protoplasts. The protoplasts are then protected by the presence of an osmotic stabilizer in the suspending medium. These stabilizers include sorbitol, mannitol, potassium chloride, magnesium sulfate and the like. Usually the concentration of these stabilizers varies between 0.8 M to 1.2 M. It is preferable to use about a 1.2 M solution of sorbitol in the suspension medium.

Uptake of the DNA into the host Trichoderma sp. strain is dependent upon the calcium ion concentration. Generally between about 10 Mm CaCl ₂ and 50 Mm CaCl ₂ is used in an uptake solution. Besides the need for the calcium ion in the uptake solution, other items generally included are a buffering system such as TE buffer (10 Mm Tris, Ph 7.4; 1 Mm EDTA) or 10 Mm MOPS, Ph 6.0 buffer (morpholinepropanesulfonic acid) and polyethylene glycol (PEG) . It is believed that the polyethylene glycol acts to fuse the cell membranes thus permitting the contents of the medium to be delivered into the cytoplasm of the Trichoderma sp. strain and the plasmid DNA is transferred to the nucleus. This fusion frequently leaves multiple copies of the plasmid DNA tandemly integrated into the host chromosome.

Usually a suspension containing the Trichoderma sp. protoplasts or cells that have been subjected to a permeability treatment at a density of 10 ⁸ to 10 ⁹ /ml, preferably 2 x 10 ⁸ /ml are used in transformation. These protoplasts or cells are added to the uptake solution, along with the desired linearized selectable marker having substantially homologous flanking regions on either side of said marker to form a transformation mixture. Generally a

high concentration of PEG is added to the uptake solution. From 0.1 to 1 volume of 25% PEG 4000 can be added to the protoplast suspension. However, it is preferable to add about 0.25 volumes to the protoplast suspension. Additives such as dimethyl sulfoxide, heparin, spermidine, potassium chloride and the like may also be added to the uptake solution and aid in transformation. _« .

Generally, the mixture is then incubated at approximately 0°C for a period between 10 to 30 minutes. Additional PEG is then added to the mixture to further enhance the uptake of the desired gene or DNA sequence. The 25% PEG 4000 is generally added in volumes of 5 to 15 times the volume of the transformation mixture; however, greater and lesser volumes may be suitable. The 25% PEG 4000 is preferably about 10 times the volume of the transformation mixture. After the PEG is added, the transformation mixture is then incubated at room temperature before the addition of a sorbitol and CaCl ₂ solution. The protoplast suspension is then further added to molten aliquots of a growth medium. This growth medium permits the growth of transformants only. Any growth medium can be used in the present invention that is suitable to grow the desired transformants. However, if Pyr- transformants are being selected it is preferable to use a growth medium that contains no uridine. The subsequent colonies are transferred and purified on a growth medium depleted of uridine.

At this stage, stable transformants were distinguished from unstable transformants by their faster growth rate and the formation of circular colonies with a smooth, rather than ragged outline on solid culture medium lacking uridine. Additionally, in some cases a further test of stability was made by growing the transformants on solid non-selective medium (i.e. containing uridine), harvesting spores from this culture medium and determining the percentage of these spores which will subsequently germinate and grow on selective medium lacking uridine.

In a particular embodiment of the above method, the truncated cellulases or derivatives thereof are recovered in

active form from the host cell either as a result of the appropriate post translational processing of the novel truncated cellulase or derivative thereof.

The present invention further relates to DNA gene fragments or variant DNA fragments derived from Trichoderma sp. that code for the truncated cellulase proteins or truncated cellulase protein derivatives, respectively. The DNA gene fragment or variant DNA fragment of the present invention codes for the core or binding domains of a Trichoderma sp. cellulase or derivative thereof that additionally retains the functional activity of the truncated core or binding domain, respectively. Moreover, the DNA fragment or variant thereof comprisng the sequence of the core or binding domain regions may additionally have attached thereto a linker, or hinge region DNA sequence or portion thereof wherein the encoded truncated cellulase still retains either cellulase core or binding domain activity, respectively. Furthermore, it is contemplated that additional DNA sequences that encode other proteins or enzymes of interest may be attached to the truncated DNA gene fragment or variant DNA fragment such that by following the above method of construction of vectors and expression of proteins, truncated cellulases or derivatives thereof fused to intact enzymes or proteins may be recovered. The expressed truncated cellulase fused to enzyme or protein would still retain active cellulase binding or core activity, depending on the truncated cellulase chosen to complex with the enzyme/protein.

The use of the cellulose binding domains and cellulase catalytic core domains or derivatives thereof versus using the intact cellulase enzyme may be of benefit in multiple applications. Therefore, a further aspect of the present invention is to provide methods that employ novel truncated cellulases or derivatives of truncated cellulases which provide additional benefits to the applied substrate as compared to intact cellulases. Such applications include stonewashing or biopolishing where it is contemplated that dye/colorant/pigment backstraining or redeposition can be

reduced or eliminated by employing novel truncated cellulase enzymes which have been modified so as to be devoid of a cellulose binding domain or to possess a binding domain with significantly lower affinity for cellulose, for example. In addition, it is contemplated that activity on certain substrates of interest in the textile, detergent, pulp & paper, animal feed, food, biomass industries, for example, can be significantly enhanced or diminished if the binding domain is removed or modified so as to reduce the binding affinity of the enzyme for cellulose. Also, the use of a truncated cellulase or derivative thereof described in the present invention which comprises a functional binding domain fragment, devoid of a catalytic domain or a functioning catalytic domain, may be of benefit in applications where only selected modification of the cellulosic substrate is desired. Properties which could be modified include, for example, hydration, swelling, dye diffusion and uptake, hand, friction, softness, cleaning, and/or surface or structural modification.

It is further contemplated that expression and use of some catalytic domains of cellulase enzymes would provide improved recoverability of enzyme, selectivity where lower activity on more crystalline substrate is desired or selectivity where high activity on amorphous/soluble substrate is desired.

Furthermore, catalytic domains of cellulase enzymes may be useful to enhance synergy with other cellulase components, cellulase or non-cellulase domains, and/or other enzymes or portions thereof on cellulosics cellulose containing materials in applications such as biomass conversion, cleaning, stonewashing, biopolishing of textiles, softening, pulp/paper processing, animal feed utilization, plant protection and pest control, starch processing, or production of pharmaceutical intermediates, disaccharides, or oligosaccharides.

Moreover, uses of cellulase catalytic core domains or derivatives thereof may reduce some of the detrimental properties associated with the intact enzyme on cellulosics such as pulps, cotton or other fibers, or paper. Properties

of interest include fiber/fabric strength loss, fiber/fabric weight loss, lint generation, and fibrillation damage.

It is further contemplated that cellulase catalytic core domains may exhibit less fiber roughing or reduced colorant redeposition/backstaining. Furthermore, these truncated catalytic core cellulases or derivatives thereof may offer an option for improved recovery/recycling of these novej cellulases.

Additionally, it is contemplated that the cellulase catalytic core domains or derivatives thereof in the present invention may contain selective activity advantages where hydrolysis of the soluble or more amorphous cellulosic regions of the substrate is desired but hydrolysis of the more crystalline region is not. This may be of importance in applications such as bioconversion where selective modification of the grain/fibers/plant materials is of interest.

Yet another aspect for applying the novel cellulase catalytic core domains or derivatives is in the generation of microcrystalline cellulose (MCC) . Furthermore, it is contemplated that the MCC will contain less bound enzyme or that the bound enzyme may be more easibly removed.

It is further contemplated that novel covalently linked truncated cellulase domain derivatives described above may have application in controlling the access of an enzyme or modified enzyme to a substrate. This may include controlling the access of proteases to wool or other materials which contain protease substrates, or controlling the access of cellulose to cellulosics, for example.

Finally, it is contemplated that novel truncated cellulases or derivatives thereof may be applied in unique mono-, dual, or multienzyme systems. As examples this may include linking cellulase domains with each other and/or with one or more protease, cellulase, lipase, and/or amylase enzymes. The enzymes or cellulase domains may be fused with a linker region in between. This linker region may be a peptide of no functional benefit or may contain the cellulose binding

domain peptide or a peptide with high affinity for other substrates or substances, such as wool, xylan, annan, resins, lignins, dyes, colorants, pigments, waxes, plastics, carbohydrate polymers, lipids, amino acid polymers, synthetic polymers, for example.

It is contemplated that novel cellulase domains or derivatives thereof of the present invention may provide some performance properties similar to or in excess of the intact enzyme. The novel truncated cellulases may provide these properties alone or may show synergistic benefits with cellulases or cellulase cores, other enzymes (for example, lipases, proteases, amylases, xylanases, peroxidases, reductases, esterases) , other proteins or chemicals. These properties may include roughening or smoothening of the cellulosic surface, modification of the cellulosics for improved response to other enzymes such as in cleaning or pulp processing, animal feed utilization or for improved biochemical/chemical uptake by cellulosics (including plant cell walls) .

It is yet further contemplated that truncated cellulase binding domains, derivatives thereof or truncated covalently linked cellulase domain derivatives in the present invention may provide enhanced or synergistic activity on cellulosics with endoglucanases and/or exocellobiohydrolases, modified cellulases or complete cellulase systems. They may also provide adhesive properties in linking cellulosic materials.

Moreover, it is contemplated that novel truncated cellulase binding domains or derivatives or the covalently linked truncated cellulase domain derivatives thereof may find application as new ligands for purification purposes, as reagents or ligands for modification of cellulosics, or other polymers, for example, linking colorants, dyes, inks, finishers, resins, chemicals, biochemicals or proteins to cellulosics. These materials can be removed at any stage, if desired, with proteases or other chemical methods. In addition, it is contemplated that the novel truncated cellulase binding domains or covalently linked truncated

cellulose domain derivatives may be used in detection and analysis of trace levels of substances, for example, the truncated domains and derivatives as well as the covalently linked truncated cellulase domain derivatives may contain proteins or chemicals which react with or bind to a substance causing it visualization e.g., dye.

Finally, it is contemplated that novel truncated binding or core domain cellulases or derivatives thereof may be complexed or fused to intact cellulases, other cellulase core or binding domains or other enzymes/proteins to improve stability, or other performance properties such as modification of pH or temperature activity profiles.

All publications and patent applications mentioned in this specification are herein incorporated by reference.

In order to further illustrate the present invention and advantages thereof, the following specific examples are given with the understanding that they are being offered to illustrate the present invention and should not be construed in any way as limiting its scope.

EXAMPLES

Example 1. Cloning and Expression of EGI Core Domain Using its Own Promoter, Terminator and Signal Sequence.

Part l. Cloning.

The complete egll gene used in the construction of the EGI core domain expression plasmid, PEGlΔ3'pyr, was obtained from the plasmid PUC218::EG1. (See FIG.6.) The 3' terminator region of egll was ligated into PUC218 (Korman, D. et al Curr Genet 17:203-212, 1990) as a 300 bp Bsml-EcoRI fragment along with a synthetic linker designed to replace the 3 ' intron and cellulose binding domain with a stop codon and continue with the egll terminator sequences. The resultant plasmid, PEG1T, was digested with Hindlll and BsmI and the vector fragment was isolated from the digest by agarose gel electrophoresis

followed by electroelution. The egll gene promoter sequence and core domain of egll were isolated from PUC218::EG1 as a 2.3kb Hindlll-SstI fragment and ligated with the same synthetic linker fragment and the Hindlll-Bsml digested PEGIT to form PEG1Δ3'

The net result of these operations is to replace the 3 ' intron and cellulose binding domain of egll with synthetic oligonucleotides of 53 and 55bp. These place a TAG stop codon after serine 415 and thereafter continued with the egll terminator up to the BsmI site.

Next, the T. longibrachiatum selectable marker, pyr4. was obtained from a previous clone p219M (Smith et al 1991) , as an isolated 1.6kb EcoRI-Hindlll fragment. This was incorporated into the final expression plasmid, PEGlΔ3 ^/ pyr, in a three way ligation with PUC18 plasmid digested with EcoRI and dephosphorylated using calf alkaline phosphatase and a Hindlll-EcoRI fragment containing the egll core domain from PEG1Δ3'.

Part 2. Transformation and Expression.

A large scale DNA prep was made of PEGlΔ3 ^, pyr and from this the EcoRI fragment containing the egll core domain and pyr4 gene was isolated by preparative gel electrophoresis. The isolated fragment was transformed into the uridine auxotroph version of the quad deleted strain, 1A52 pyrl3 (described in U.S. Patent Application Serial Nos. 07/770,049, 08/048,728 and 08/048,881, incorporated by reference in its entirety herein) , and stable transformants were identified.

To select which transformants expressed egll core domain the transformants were grown up in shake flasks under conditions that favored induction of the cellulase genes (Vogels + 1% lactose) . After 4-5 days of growth, protein from the supernatants was concentrated and either 1) run on SDS polyacrylamide gels prior to detection of the egll core domain by Western analysis using EGI polyclonal antibodies or 2) the concentrated supernatants were assayed directly using RBB carboxy methyl cellulose as an endoglucanase specific

substrate and the results compared to the parental strain 1A52 as a control. Transformant candidates were identified as possibly producing a truncated EGI core domain protein. Genomic DNA and total MRNA was isolated from these strains following growth on Vogels + 1% lactose and Southern and Northern blot experiments performed using an isolated DNA fragment containing only the egll core domain. These experiments demonstrated that transformants could be isolated having a copy of the egll core domain expression cassette integrated into the genome of 1A52 and that these same transformants produced egll core domain MRNA.

One transformant was then grown using media suitable for cellulase production in Trichoderma well known in the art that was supplemented with lactose (Warzymoda, M. et al 1984 French Patent No. 2555603) in a 14L fermentor. The resultant broth was concentrated and the proteins contained therein were separated by SDS polyacrylamide gel electrophoresis and the Egll core domain protein identified by Western analysis. (See Example 3 below) . It was subsequently estimated that the protein concentration of the fermentation supernatant was about 5-6 g/L of which approximately 1.7-4.4g/L was EGI core domain based on CMCase activity. This value is based on an average of several EGI core fermentations that were performed.

In a similar manner, any other cellulase domain or derivative thereof may be produced by procedures similar to those discussed above.

Example 2. Purification of EGI and EGII catalytic cores

Part 1. EGI catalytic core

The EGI core was purified in the following manner. The concentrated (UF) broth was filtered using diatomaceous earth and ammonium sulfate was added to the broth to a final concentration of IM (NH4)2S04. This was then loaded onto a hydrophobic column (phenyl-sepharose fast flow, Pharmacia, cat # 17-0965-02) and eluted with a salt gradient from IM to OM

(NH4) ₂ S04. The fractions which contained the EGI core were then pooled and exchanged into 10 mM TES pH 7.5. This solution was then loaded onto an anion exchange column (Q- sepharose fast flow, Pharmacia Cat # 17-0510-01) and eluted in a gradient from 0 to IM NaCl in 10 mM TES pH 7.5. The most pure fractions were desalted into 10 mM TES pH 7.5 and loaded onto a MONO Q column. The EGI core elution was carried out with a gradient from 0 to IM NaCl. The resulting fractions were greater than 85% pure. The most pure fraction was sequence verified to be the EGI core.

Part 2. EGII catalytic core

It is contemplated that the purification of the EGII catalytic core is similar to that of EGII cellulase because of its similar biochemical properties. The theoretical pi of the EGII core is less than a half a pH unit lower than that of EGII. Also, EGII core is approximately 80% of the molecular weight of EGII. Therefore, the following purification protocol is based on the purification of EGII. The method may involve filtering the UF concentrated broth through diatomaceous earth and adding (NH4)2S04 to bring the solution to IM (NH4)2S04. This solution may then be loaded onto a hydrophobic column (phenyl-sepharose fast flow, Pharmacia, cat #17-0965-02) and the EGII may be step eluted with 0.15 M (NH4)2S04. The fractions containing the EGII core may then be buffer exchanged into citrate-phosphate pH 7, 0.18 Ohm. This material may then be loaded onto a anion exchange column (Q- sepharose fast flow, Pharmacia, cat. #17-0510-01) equilibrated in the above citrate-phosphate buffer. It is expected that EGII core will not bind to the column and thus be collected in the flow through.

Example 3. Cloning and Expression of CBHII Core Domain Using the CBHI Promoter, Terminator and Signal Sequence from CBHII.

Part 1. Construction of the T.longibrachiatum general-purpose expression plasmid-PTEX.

The plasmid, PTEX was constructed following the methods of Sambrook et al. (1989), supra. and is illustrated in FIG. 7. This plasmid has been designed as a multi-purpose expression vector for use in the filamentous fungus Trichoderma longibrachiatum. The expression cassette has several unique features that make it useful for this function. Transcription is regulated using the strong CBH I gene promoter and terminator sequences for T. longibrachiatum. Between the CBHI promoter and terminator there are unique Pmel and SstI restriction sites that are used to insert the gene to be expressed. The T. longibrachiatum pyr4 selectable marker gene has been inserted into the CBHI terminator and the whole expression cassette (CBHI promoter-insertion sites-CBHI terminator-pyr4 gene-CBHI terminator) can be excised utilizing the unique Notl restriction site or the unique Notl and Nhel restriction sites.

This vector is based on the bacterial vector, pSL1180 (Pharmacia Inc. , Piscataway, New Jersey) , which is a PUC-type vector with an extended multiple cloning site. One skilled in the art would be able to construct this vector based on the flow diagram illustrated in FIG 7. (See also U.S. patent application 07/954,113 for the construction of PTEX expression plasmid.)

It would be possible to construct plasmids similar to PTEX-truncated cellulases or derivatives thereof described in the present invention containing any other piece of DNA sequence replacing the truncated cellulase gene.

Part 2. Cloning.

The complete cbh2 gene used in the construction of the CBHII core domain expression plasmid, PTEX CBHII core, was obtained from the plasmid PUC219::CBHII (Korman, D. et al, 1990, Curr Genet 17:203-212). The cellulose binding domain, positioned at the 5' end of the cbh2 gene, is conveniently located between an Xbal and SnaBI restriction sites^ In order to utilize the Xbal site an additional Xbal site in the polylinker was destroyed. PUC219::CBHII was partially digested with Xbal such that the majority of the product was linear. The Xbal overhangs were filled in using T4 DNA polymerase and ligated together under conditions favoring self ligation of the plasmid. This has the effect of destroying the blunted site which, in 50% of the plasmids, was the Xbal site in the polylinker. Such a plasmid was identified and digested with Xbal and SnaBI to release the cellulose binding domain. The vector-CBHII core domain was isolated and ligated with the following synthetic oligonucleotides designed to join the Xbal site with the SnaBI site at the signal peptidase cleavage site and papain cleavage point in the linker domain.

Xbal SnaBI

5' CTA GAG CGG TCG GGA ACC GCT AC 3' (Seq ID No: 44) 3' TC CTC GCC AGC CCT TGG CGA TG 5' Leu Glu Glu Arg Ser Gly Thr Ala Thr (Seq ID No: 45)

The resultant plasmid, pUCΔCBD CBHII, was digested with Nhel and the ends blunted by incubation with T4 DNA polymerase and dNTPs. After which the linear blunted plasmid DNA was digested with Bglll and the Nhe (blunt) Bglll fragment containing the CBHII signal sequence and core domain was isolated.

The final expression plasmid was engineered by digesting the general purpose expression plasmid, pTEX (disclosed in 07/954,113, incorporated in its entirety by references, and described in Part 3 below) , with Sstll and P el and ligating the CBHII Nhel (blunt)-Bglll fragment downstream of the cbhl

promoter using a synthetic oligonucleotide having the sequence CGCTAG to fill in the Bglll overhang with the Sstll overhang. The pTEX-CBHI core expression plasmid was prepared in a similar manner as pTEX-CBHII core described in the above example. Its construction is exemplified in Figure 8.

Part 3. Transformation and Expression.

A large scale DNA prep was made of pTEX CBHIIcore and from this the Notl fragment containing the CBHII core domain under the control of the cbhl transcriptional elements and pyr4 gene was isolated by preparative gel electrophoresis. The isolated fragment was transformed into the uridine auxotroph version of the quad deleted strain, 1A52 pyrl3, and stable transformants were identified.

To select which transformants expressed cbh2 core domain genomic DNA was isolated from strains following growth on Vogels + 1% glucose and Southern blot experiments performed using an isolated DNA fragment containing only the cbh2 core domain. Transformants were isolated having a copy of the cbh2 core domain expression cassette integrated into the genome of 1A52. Total mRNA was isolated from the two strains following growth for 1 day on Vogels + 1% lactose. The mRNA was subjected to Northern analysis using the cbh2 coding region as a probe. Transformants expressing cbh2 core domain mRNA were identified.

Two transformants were grown under the same conditions as previously described in Example 1 in 14L fermentors. The resultant broth was concentrated and the proteins contained therein were separated by SDS polyacrylamide gel electrophoresis and the CBHII core domain protein identified by Western analysis. One transformant, #15, produced a protein of the correct size and reactivity to CBHII polyclonal antibodies.

It was subsequently estimated that the protein concentration of the fermentation supernatant after purification was lOg/L of which 30-50% was CBHII core domain (See Example 4) .

One may obtain any other novel truncated cellulase core domain protein or derivative thereof by employing the methods described above.

Example 4. Purification of CBHI and CBHII catalytic cores

Part 1. CBHI catalytic core.

The CBHI core was purified from broth obtained from T. longibrachiaturn harboring pTEX-CBHI core expression vector in the following manner. The CBHI core ultrafiltered (UF) broth was filtered using diatomaceous earth and diluted in 10 mM TES pH 6.8 to a conductivity of 1.5 mOhm. The diluted CBHI core was then loaded onto an anion exchange column (Q-Sepharose fast flow, Pharmacia cat # 17-0510-01) equilibrated in 10 mM TES pH 6.8 The CBHI core was separated from the majority of the other proteins in the broth using a gradient elution in 10 mM TES pH 6.8 from 0 to IM NaCl. The fractions containing the CBHI core were then concentrated on an Amicon stirred cell concentrator with a PM 10 membrane (diaflo ultra filtration membranes, Amicon Cat # 13132MEM 5468A) . This step concentrated the core as well as separated it from lower molecular weight proteins. The resulting fractions were greater than 85% pure CBHI core. The purest fraction was sequence verified to be the CBHI core.

Part 2. CBHII catalytic core.

It is predicted that CBHII catalytic core will purify in a manner similar to that of CBHII cellulase because of its similar biochemical properties. The theoretical pi of the CBHII core is less than half a pH unit lower than that of CBHII. Additionally, CBHII catalytic core is approximately 80% of the molecular weight of CBHII. Therefore, the following proposed purification protocol is based on the purification method used for CBHII. The diatomaceous earth treated, ultra filtered (UF) CBHII core broth is diluted into 10 mM TES pH 6.8 to a conductivity of <0.7 mOhm. The diluted

CBHII core is then loaded onto an anion exchange column (Q- Sepharose fast flow, Pharmacia, cat # 17 0510-01) equilibrated in 10 mM TES pH 6.8. A salt gradient from 0 to IM NaCl in 10 mM TES pH 6.8 is used to elute the CBHII core off the column. The fractions which contain the CBHII core is then buffer exchanged into 2mM sodium succinate buffer and loaded onto a cation exchange column (SP-sephadex C-50) . The CBHII core is next eluted from the column with a salt gradient from 0 to lOOmM NaCl.

Example 5. Cloning and Expression of CBHII Cellulose Binding Domain Using the CBHI Promoter.

Part 1. Cloning.

The complete cbh2 gene used in the construction of the CBHII core domain expression plasmid, pTEX CBHIIcore, was obtained from the plasmid pUC219::CBHII. The cellulose binding domain, positioned at the 5' end of the cbh2 gene, was obtained by digestion of PUC219: :CBHII with Bglll and Nsil and isolating the 450bp Bglll-Nsil restriction fragment. The final expression plasmid, PTEX CBHII CBD was engineered by digesting the general purpose expression plasmid, PTEX (described in 07/954,113 and incorporated herein by reference in its entirety) , with Sstll and Pmel and ligating the CBHII CBD Bglll-Nsil fragment downstream of the cbhl promoter using a synthetic oligonucleotide having the sequence 3 ' CGCTAG 5' to fill in the Bglll overhang with the SstII overhang and the following synthetic linker to link the Nsil site with the blunt Pmel site of pTEX. (See FIG 9) .

3' ACGT ATA ATG ATT 5'

Nsil *** *** Stop codons

When the final expression plasmid, pTEX CBHII CBD, was sequenced across the linker junctions it was discovered that

the sticky Nsil site had ligated directly to the blunt Pmel site in pTEX. This means that the reading frame of the CBHII CBD continues on through the Pmel linker and into the cbhl terminator for a further 12 amino acids as follows;

5' AAA CCC CGG GTG ATT TAT TTT TTT TGT ATC TAC TTC TGA 3' 3'TTT GGG GCC CAC TAA ATA AAA AAA ACA TAG ATG AAG ACT 5'

(Seg ID No: 46) ys Pro Arg Val lie Tyr Phe Phe Cys lie Tyr Phe ***

(Seg ID No: 47)

However, the addition of these additional amino acids is not thought to significantly change the properties of the cellulose binding domain.

In a similar fashion, it is contemplated that any one of the other known binding domains may be substituted in the above pTEX construct to provide expression of the substituted binding domains by following the general format disclosed above.

Part 2. Transformation and Expression.

A large scale DNA prep was made of pTEX CBHII CBD and from this the Notl fragment containing the CBHII core domain under the control of the cbhl transcriptional elements and pyr4 gene was isolated by preparative gel electrophoresis. The isolated fragment was transformed into the uridine auxotroph version of the quad deleted strain, 1A52 pyrl3, and stable transformants were identified.

To select which transformants expressed cbh2 cellulose binding domain, genomic DNA was isolated from all stably transformant strains following growth on Vogels + 1% glucose and Southern blot experiments performed using an isolated DNA fragment containing the cbhl gene to identify the transformants containing the CBHII CBD PTEX expression vector.

Total mRNA was isolated from the transformed strains following growth for 1 day on Vogels + 1% lactose. The MRNA was subjected to Northern analysis using the cbh2 coding region as a probe. Most of the transformants expressed cbh2

CBD MRNA at high levels. One transformant was selected and grown under conditions previously described in a 14L fermentor. The resultant broth was concentrated and the proteins contained therein were separated by SDS polyacrylamide gel electrophoresis and the CBHII CBD protein subjected to Western analysis. A protein of the expected size was identified by reactivity to CBHII CBD polyclonal. antibodies raised against the synthetic CBHII CBD peptide having the sequence;

NH2 C-G-G-Q-N-V-S-G-P-T-C-C-A-S-G-S-T-C-COOH

(Seq ID No: 48)

Example 6 Purification of Cellulose Binding Domains

The binding domain can ben purified by methods similar to those reported in the literature (Ong, E. , et al 1989 Bio/Technology 7: 604-607). In the case of affinity chromatography, the filtered binding domain broth can be contacted with a cellulosic substance, such as avicel or pulp/paper. The cellulosic solids may be separated by centrifugation or filtration. Alternatively, the filtered broth may be passed over a cellulosic-type column. The bound binding domains may then be eluted by treatment with distilled water, guanidinium HCl/other denaturants, surfactants, or other appropriate elution chemicals. Use of temperature modification may also be an option. Affinity chromatography using antibodies generated against the CBD or CBD derivative may also be employed. A particular purification procedure may require several fractionation steps depending upon the sample matrix and upon the chemical properties of the binding domains and modified domains of the present invention. In some cases the modified domains may contain additional charged functional groups which may allow for the use of other methods such as ionic exchange.

While the invention has been described in terms of various preferred embodiments, the skilled artisan will

appreciate that various modifications, substitutions, omissions, and changes may be made without departing from the scope and spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims, including equivalents thereof.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Fowler, Timothy Ward, Michael Clarkson, Kathleen Collier, Katherine Larenas, Edmund

(ii) TITLE OF INVENTION: Novel Cellulase Enzymes and Systems For Their Expression

(iii) NUMBER OF SEQUENCES: 48

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Genencor International

(B) STREET: 180 Kimball Way

(C) CITY: South San Francisco

(D) STATE: CA

(E) COUNTRY: USA

(F) ZIP: 94080

(V) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: 08/169,948

(B) FILING DATE: DEC 17 1993

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Horn, Margaret A.

(B) REGISTRATION NUMBER: 33,401

(C) REFERENCE/DOCKET NUMBER: GC226

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (415) 742-7536

(B) TELEFAX: (415)742-7217

(2) INFORMATION FOR SEQ ID NO:l:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..93

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:

GGC CAG TGC GGC GGT ATT GGC TAC AGC GGC CCC ACG GTC TGC GCC AGC 48 Gly Gin Cys Gly Gly lie Gly Tyr Ser Gly Pro Thr Val Cys Ala Ser 1 5 10 15

GGC ACA ACT TGC CAG GTC CTG AAC CCT TAC TAC TCT CAG TGC CTG 93

Gly Thr Thr Cys Gin Val Leu Asn Pro Tyr Tyr Ser Gin Cys Leu 20 25 30

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly Gin Cys Gly Gly lie Gly Tyr Ser Gly Pro Thr Val Cys Ala Ser 1 5 10 15

Gly Thr Thr Cys Gin Val Leu Asn Pro Tyr Tyr Ser Gin Cys Leu 20 25 30

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 166 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..20, 70..166)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CAA GCT TGC TCA AGC GTC TG GTAATTATGT GAACCCTCTC AAGAGACCCA 50

Gin Ala Cys Ser Ser Val Trp 1 5

AATACTGAGA TATGTCAAG G GGC CAA TGT GGT GGC CAG AAT TGG TCG GGT 100

Gly Gin Cys Gly Gly Gin Asn Trp Ser Gly 10 15

CCG ACT TGC TGT GCT TCC GGA AGC ACA TGC GTC TAC TCC AAC GAC TAT 148 Pro Thr Cys Cys Ala Ser Gly Ser Thr Cys Val Tyr Ser Asn Asp Tyr 20 25 30

TAC TCC CAG TGT CTT CCC 166

Tyr Ser Gin Cys Leu Pro 35

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gin Ala Cys Ser Ser Val Trp Gly Gin Cys Gly Gly Gin Asn Trp Ser 1 5 10 15

Gly Pro Thr Cys Cys Ala Ser Gly Ser Thr Cys Val Tyr Ser Asn AS-D 20 25 30

Tyr Tyr Ser Gin Cys Leu Pro 35

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 156 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..82, 140..156)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CAC TGG GGG CAG TGC GGT GGC ATT GGG TAC AGC GGG TGC AAG ACG TGC 48 His Trp Gly Gin Cys Gly Gly lie Gly Tyr Ser Gly Cys Lys Thr Cys 1 5 10 15

ACG TCG GGC ACT ACG TGC CAG TAT AGC AAC GAC T GTTCGTATCC 92

Thr Ser Gly Thr Thr Cys Gin Tyr Ser Asn Asp 20 25

CCATGCCTGA CGGGAGTGAT TTTGAGATGC TAACCGCTAA AATACAG AC TAC TCG 147

Tyr Tyr Ser 30

CAA TGC CTT 156

Gin Cys Leu

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

His Trp Gly Gin Cys Gly Gly lie Gly Tyr Ser Gly Cys Lys Thr Cyp 1 5 10 15

Thr Ser Gly Thr Thr Cys Gin Tyr Ser Asn Asp Tyr Tyr Ser Gin Cys 20 25 30

Leu

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..108

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CAG CAG ACT GTC TGG GGC CAG TGT GGA GGT ATT GGT TGG AGC GGA CCT 48 Gin Gin Thr Val Trp Gly Gin Cys Gly Gly lie Gly Trp Ser Gly Pro 1 5 10 15

ACG AAT TGT GCT CCT GGC TCA GCT TGT TCG ACC CTC AAT CCT TAT TAT 96 Thr Asn Cys Ala Pro Gly Ser Ala Cys Ser Thr Leu Asn Pro Tyr Tyr 20 25 30

GCG CAA TGT ATT 108

Ala Gin Cys lie 35

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Gin Gin Thr Val Trp Gly Gin Cys Gly Gly lie Gly Trp Ser Gly Pro 1 5 10 15

Thr Asn Cys Ala Pro Gly Ser Ala Cys Ser Thr Leu Asn Pro Tyr Tyr 20 25 30

Ala Gin Cys lie 35

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1453 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..410, 478..1174, 1238..1453)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CAG TCG GCC TGC ACT CTC CAA TCG GAG ACT CAC CCG CCT CTG ACA TGG 48

Gin Ser Ala Cys Thr Leu Gin Ser Glu Thr His Pro Pro Leu Thr Trp 1 5 10 15

CAG AAA TGC TCG TCT GGT GGC ACT TGC ACT CAA CAG ACA GGC TCC GTG 96 Gin Lys Cys Ser Ser Gly Gly Thr Cys Thr Gin Gin Thr Gly Ser Val 20 25 30

GTC ATC GAC GCC AAC TGG CGC TGG ACT CAC GCT ACG AAC AGC AGC ACG 144 Val lie Asp Ala Asn Trp Arg Trp Thr His Ala Thr Asn Ser Ser Thr 35 40 45

AAC TGC TAC GAT GGC AAC ACT TGG AGC TCG ACC CTA TGT CCT GAC AAC 192 Asn Cys Tyr Asp Gly Asn Thr Trp Ser Ser Thr Leu Cys Pro Asp Asn 50 55 60

GAG ACC TGC GCG AAG AAC TGC TGT CTG GAC GGT GCC GCC TAC GCG TCC 240 Glu Thr Cys Ala Lys Asn Cys Cys Leu Asp Gly Ala Ala Tyr Ala Ser 65 70 75 80

ACG TAC GGA GTT ACC ACG AGC GGT AAC AGC CTC TCC ATT GGC TTT GTC 288 Thr Tyr Gly Val Thr Thr Ser Gly Asn Ser Leu Ser lie Gly Phe Val 85 90 95

ACC CAG TCT GCG CAG AAG AAC GTT GGC GCT CGC CTT TAC CTT ATG GCG 336 Thr Gin Ser Ala Gin Lys Asn Val Gly Ala Arg Leu Tyr Leu Met Ala 100 105 110

AGC GAC ACG ACC TAC CAG GAA.TTC ACC CTG CTT GGC AAC GAG TTC TCT 384 Ser Asp Thr Thr Tyr Gin Glu Phe Thr Leu Leu Gly Asn Glu Phe Ser 115 120 125

TTC GAT GTT GAT GTT TCG CAG CTG CC GTAAGTGACT TACCATGAAC 430

Phe Asp Val Asp Val Ser Gin Leu Pro 130 135

CCCTGACGTA TCTTCTTGTG GGCTCCCAGC TGACTGGCCA ATTTAAG G TGC GGC 484

Cys Gly

TTG AAC GGA GCT CTC TAC TTC GTG TCC ATG GAC GCG GAT GGT GGC GTG 532 Leu Asn Gly Ala Leu Tyr Phe Val Ser Met Asp Ala Asp Gly Gly Val 140 145 150 155

AGC AAG TAT CCC ACC AAC ACC GCT GGC GCC AAG TAC GGC ACG GGG TAC 580 Ser Lys Tyr Pro Thr Asn Thr Ala Gly Ala Lys Tyr Gly Thr Gly Tyr 160 165 170

TGT GAC AGC CAG TGT CCC CGC GAT CTG AAG TTC ATC AAT GGC CAG GCC 628 Cys Asp Ser Gin Cys Pro Arg Asp Leu Lys Phe He Asn Gly Gin Alε 175 180 185

AAC GTT GAG GGC TGG GAG CCG TCA TCC AAC AAC GCA AAC ACG GGC ATT 676 Asn Val Glu Gly Trp Glu Pro Ser Ser Asn Asn Ala Asn Thr Gly He 190 195 200

GGA GGA CAC GGA AGC TGC TGC TCT GAG ATG GAT ATC TGG GAG GCC AAC 724 Gly Gly His Gly Ser Cys Cys Ser Glu Met Asp He Trp Glu Ala Asn 205 210 215

TCC ATC TCC GAG GCT CTT ACC CCC CAC CCT TGC ACG ACT GTC GGC CAG 772 Ser He Ser Glu Ala Leu Thr Pro His Pro Cys Thr Thr Val Gly Gin 220 225 230 235

GAG ATC TGC GAG GGT GAT GGG TGC GGC GGA ACT TAC TCC GAT AAC AGA 820 Glu He Cys Glu Gly Asp Gly Cys Gly Gly Thr Tyr Ser Asp Asn Arg 240 245 250

TAT GGC GGC ACT TGC GAT CCC GAT GGC TGC GAC TGG AAC CCA TAC CGC 868 Tyr Gly Gly Thr Cys Asp Pro Asp Gly Cys Asp Trp Asn Pro Tyr Arg 255 260 265

CTG GGC AAC ACC AGC TTC TAC GGC CCT GGC TCA AGC TTT ACC CTC GAT 916 Leu Gly Asn Thr Ser Phe Tyr Gly Pro Gly Ser Ser Phe Thr Leu Asp 270 275 280

ACC ACC AAG AAA TTG ACC GTT GTC ACC CAG TTC GAG ACG TCG GGT GCC 964 Thr Thr Lys Lys Leu Thr Val Val Thr Gin Phe Glu Thr Ser Gly Ala 285 290 295

ATC AAC CGA TAC TAT GTC CAG AAT GGC GTC ACT TTC CAG CAG CCC AAC 1012 He Asn Arg Tyr Tyr Val Gin Asn Gly Val Thr Phe Gin Gin Pro Asn 300 305 310 315

GCC GAG CTT GGT AGT TAC TCT GGC AAC GAG CTC AAC GAT GAT TAC TGC 1060 Ala Glu Leu Gly Ser Tyr Ser Gly Asn Glu Leu Asn Asp Asp Tyr Cys 320 325 330

ACA GCT GAG GAG GCA GAA TTC GGC GGA TCC TCT TTC TCA GAC AAG GGC 1108 Thr Ala Glu Glu Ala Glu Phe Gly Gly Ser Ser Phe Ser Asp Lys Gly 335 340 345

GGC CTG ACT CAG TTC AAG AAG GCT ACC TCT GGC GGC ATG GTT CTG GTC 1156 Gly Leu Thr Gin Phe Lys Lys Ala Thr Ser Gly Gly Met Val Leu Val 350 355 360

ATG AGT CTG TGG GAT GAT GTGAGTTTGA TGGACAAACA TGCGCGTTGA 1204

Met Ser Leu Trp Asp Asp 365

CAAAGAGTCA AGCAGCTGAC TGAGATGTTA CAG TAC TAC GCC AAC ATG CTG TGG 1258

Tyr Tyr Ala Asn Met Leu Trp 370 375

CTG GAC TCC ACC TAC CCG ACA AAC GAG ACC TCC TCC ACA CCC GGT GCC 1306

Leu Asp Ser Thr Tyr Pro Thr Asn Glu Thr Ser Ser Thr Pro Gly Ala 380 385 390

GTG CGC GGA AGC TGC TCC ACC AGC TCC GGT GTC CCT GCT CAG GTC GAA 1354 Val Arg Gly Ser Cys Ser Thr Ser Ser Gly Val Pro Ala Gin Val Glu 395 400 405

TCT CAG TCT CCC AAC GCC AAG GTC ACC TTC TCC AAC ATC AAG TTC GGA 1402 Ser Gin Ser Pro Asn Ala Lys Val Thr Phe Ser Asn He Lys Phe Gly 410 415 420

CCC ATT GGC AGC ACC GGC AAC CCT AGC GGC GGC AAC CCT CCC GGC GGΛ 1450 Pro He Gly Ser Thr Gly Asn Pro Ser Gly Gly Asn Pro Pro Gly Gly 425 430 435 440

AAC 1453

Asn

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 441 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Gin Ser Ala Cys Thr Leu Gin Ser Glu Thr His Pro Pro Leu Thr Trp 1 5 10 15

Gin Lys Cys Ser Ser Gly Gly Thr Cys Thr Gin Gin Thr Gly Ser Val 20 25 30

Val He Asp Ala Asn Trp Arg Trp Thr His Ala Thr Asn Ser Ser Thr 35 40 45

Asn Cys Tyr Asp Gly Asn Thr Trp Ser Ser Thr Leu Cys Pro Asp Asn 50 55 60

Glu Thr Cys Ala Lys Asn Cys Cys Leu Asp Gly Ala Ala Tyr Ala Ser 65 70 75 80

Thr Tyr Gly Val Thr Thr Ser Gly Asn Ser Leu Ser He Gly Phe Val 85 90 95

Thr Gin Ser Ala Gin Lys Asn Val Gly Ala Arg Leu Tyr Leu Met Ala 100 105 110

Ser Asp Thr Thr Tyr Gin Glu Phe Thr Leu Leu Gly Asn Glu Phe Ser 115 120 125

Phe Asp Val Asp Val Ser Gin Leu Pro Cys Gly Leu Asn Gly Ala Leu 130 135 140

Tyr Phe Val Ser Met Asp Ala Asp Gly Gly Val Ser Lys Tyr Pro Thr 145 150 155 160

Asn Thr Ala Gly Ala Lys Tyr Gly Thr Gly Tyr Cys Asp Ser Gin Cys 165 170 175

Pro Arg Asp Leu Lys Phe He Asn Gly Gin Ala Asn Val Glu Gly Trp 180 185 190

Glu Pro Ser Ser Asn Asn Ala Asn Thr Gly He Gly Gly His Gly Ser 195 200 205

Cys Cys Ser Glu Met Asp He Trp Glu Ala Asn Ser He Ser Glu Ala 210 215 220

Leu Thr Pro His Pro Cys Thr Thr Val Gly Gin Glu He Cys Glu Gly 225 230 235 240

Asp Gly Cys Gly Gly Thr Tyr Ser Asp Asn Arg Tyr Gly Gly Thr Cys 245 250 255

Asp Pro Asp Gly Cys Asp Trp Asn Pro Tyr Arg Leu Gly Asn Thr Ser 260 265 270

Phe Tyr Gly Pro Gly Ser Ser Phe Thr Leu Asp Thr Thr Lys Lys Leu 275 280 285

Thr Val Val Thr Gin Phe Glu Thr Ser Gly Ala He Asn Arg Tyr Tyr 290 295 300

Val Gin Asn Gly Val Thr Phe Gin Gin Pro Asn Ala Glu Leu Gly Ser 305 310 315 320

Tyr Ser Gly Asn Glu Leu Asn Asp Asp Tyr Cys Thr Ala Glu Glu Ala 325 330 335

Glu Phe Gly Gly Ser Ser Phe Ser Asp Lys Gly Gly Leu Thr Gin Phe 340 345 350

Lys Lys Ala Thr Ser Gly Gly Met Val Leu Val Met Ser Leu Trp Asp 355 360 365

Asp Tyr Tyr Ala Asn Met Leu Trp Leu Asp Ser Thr Tyr Pro Thr Asn 370 375 380

Glu Thr Ser Ser Thr Pro Gly Ala Val Arg Gly Ser Cys Ser Thr Ser 385 390 395 400

Ser Gly Val Pro Ala Gin Val Glu Ser Gin Ser Pro Asn Ala Lys Val 405 410 415

Thr Phe Ser Asn He Lys Phe Gly Pro He Gly Ser Thr Gly Asn Pro 420 425 430

Ser Gly Gly Asn Pro Pro Gly Gly Asn 435 440

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1241 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..161, 218..465, 556..1241)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TCG GGA ACC GCT ACG TAT TCA GGC AAC CCT TTT GTT GGG GTC ACT CCT 48 Ser Gly Thr Ala Thr Tyr Ser Gly Asn Pro Phe Val Gly Val Thr Pro 1 5 10 15

TGG GCC AAT GCA TAT TAC GCC TCT GAA GTT AGC AGC CTC GCT ATT CCT 96 Trp Ala Asn Ala Tyr Tyr Ala Ser Glu Val Ser Ser Leu Ala He Pro 20 25 30

AGC TTG ACT GGA GCC ATG GCC ACT GCT GCA GCA GCT GTC GCA AAG GTT 144 Ser Leu Thr Gly Ala Met Ala Thr Ala Ala Ala Ala Val Ala Lys Val 35 40 45

CCC TCT TTT ATG TGG CT GTAGGTCCTC CCGGAACCAA GGCAATCTGT 191

Pro Ser Phe Met Trp Leu 50

TACTGAAGGC TCATCATTCA CTGCAG A GAT ACT CTT GAC AAG ACC CCT CTC 242

Asp Thr Leu Asp Lys Thr Pro Leu 55 60

ATG GAG CAA ACC TTG GCC GAC ATC CGC ACC GCC AAC AAG AAT GGC GGT 290 Met Glu Gin Thr Leu Ala Asp He Arg Thr Ala Asn Lys Asn Gly Gly 65 70 75

AAC TAT GCC GGA CAG TTT GTG GTG ATA GAC TTG CCG GAT CGC GAT TGC 338 Asn Tyr Ala Gly Gin Phe Val Val He Asp Leu Pro Asp Arg Asp Cys 80 85 90

GCT GCC CTT GCC TCG AAT GGC GAA TAC TCT ATT GCC GAT GGT GGC GTC 386 Ala Ala Leu Ala Ser Asn Gly Glu Tyr Ser He Ala Asp Gly Gly Val 95 100 105 110

GCC AAA TAT AAG AAC TAT ATC GAC ACC ATT CGT CAA ATT GTC GTG GAA 434 Ala Lys Tyr Lys Asn Tyr He Asp Thr He Arg Gin He Val Val Glu 115 120 125

TAT TCC GAT ATC CGG ACC CTC CTG GTT ATT G GTATGAGTTT AAACACCTGC 485 Tyr Ser Asp He Arg Thr Leu Leu Val He 130 135

CTCCCCCCCC CCTTCCCTTC CTTTCCCGCC GGCATCTTGT CGTTGTGCTA ACTATTGTTC 545

CCTCTTCCAG AG CCT GAC TCT CTT GCC AAC CTG GTG ACC AAC CTC GGT 593 Glu Pro Asp Ser Leu Ala Asn Leu Val Thr Asn Leu Gly 140 145

ACT CCA AAG TGT GCC AAT GCT CAG TCA GCC TAC CTT GAG TGC ATC AAC 641 Thr Pro Lys Cys Ala Asn Ala Gin Ser Ala Tyr Leu Glu Cys He Asn 150 155 160 165

TAC GCC GTC ACA CAG CTG AAC CTT CCA AAT GTT GCG ATG TAT TTG GAC 689 Tyr Ala Val Thr Gin Leu Asn Leu Pro Asn Val Ala Met Tyr Leu Asp 170 175 180

#

GCT GGC CAT GCA GGA TGG CTT GGC TGG CCG GCA AAC CAA GAC CCG GCC 737 Ala Gly His Ala Gly Trp Leu Gly Trp Pro Ala Asn Gin Asp Pro Ala 185 190 195

GCT CAG CTA TTT GCA AAT GTT TAC AAG AAT GCA TCG TCT CCG AGA GCT 785 Ala Gin Leu Phe Ala Asn Val Tyr Lys Asn Ala Ser Ser Pro Arg Ala 200 205 210

CTT CGC GGA TTG GCA ACC AAT GTC GCC AAC TAC AAC GGG TGG AAC ATT 833 Leu Arg Gly Leu Ala Thr Asn Val Ala Asn Tyr Asn Gly Trp Asn He 215 220 225

ACC AGC CCC CCA TCG TAC ACG CAA GGC AAC GCT GTC TAC AAC GAG AAG 881 Thr Ser Pro Pro Ser Tyr Thr Gin Gly Asn Ala Val Tyr Asn Glu Lys 230 235 240 245

CTG TAC ATC CAC GCT ATT GGA CCT CTT CTT GCC AAT CAC GGC TGG TCC 929 Leu Tyr He His Ala He Gly Pro Leu Leu Ala Asn His Gly Trp Ser 250 255 260

AAC GCC TTC TTC ATC ACT GAT CAA GGT CGA TCG GGA AAG CAG CCT ACC 977 Asn Ala Phe Phe He Thr Asp Gin Gly Arg Ser Gly Lys Gin Pro Thr 265 270 275

GGA CAG CAA CAG TGG GGA GAC TGG TGC AAT GTG ATC GGC ACC GGA TTT 1025 Gly Gin Gin Gin Trp Gly Asp Trp Cys Asn Val He Gly Thr Gly Phe 280 285 290

GGT ATT CGC CCA TCC GCA AAC ACT GGG GAC TCG TTG CTG GAT TCG TTT 1073 Gly He Arg Pro Ser Ala Aβn Thr Gly Asp Ser Leu Leu Asp Ser Phe 295 300 305

GTC TGG GTC AAG CCA GGC GGC GAG TGT GAC GGC ACC AGC GAC AGC AGT 1121 Val Trp Val Lys Pro Gly Gly Glu Cys Asp Gly Thr Ser Asp Ser Ser 310 315 320 325

GCG CCA CGA TTT GAC TCC CAC TGT GCG CTC CCA GAT GCC TTG CAA CCG 1169 Ala Pro Arg Phe Asp Ser His Cys Ala Leu Pro Asp Ala Leu Gin Pro 330 335 340

GCG CCT CAA GCT GGT GCT TGG TTC CAA GCC TAC TTT GTG CAG CTT CTC 1217 Ala Pro Gin Ala Gly Ala Trp Phe Gin Ala Tyr Phe Val Gin Leu Leu 345 350 355

ACA AAC GCA AAC CCA TCG TTC CTG 1241

Thr Asn Ala Asn Pro Ser Phe Leu 360 365

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 365 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Ser Gly Thr Ala Thr Tyr Ser Gly Asn Pro Phe Val Gly Val Thr Pro 1 5 10 15

Trp Ala Asn Ala Tyr Tyr Ala Ser Glu Val Ser Ser Leu Ala He Pro 20 25 30

Ser Leu Thr Gly Ala Met Ala Thr Ala Ala Ala Ala Val Ala Lys Val 35 40 45

Pro Ser Phe Met Trp Leu Asp Thr Leu Asp Lys Thr Pro Leu Met Glu 50 55 60

Gin Thr Leu Ala Asp He Arg Thr Ala Asn Lys Asn Gly Gly Asn Tyr 65 70 75 80

Ala Gly Gin Phe Val Val He Asp Leu Pro Asp Arg Asp Cys Ala Ala 85 90 95

Leu Ala Ser Asn Gly Glu Tyr Ser He Ala Asp Gly Gly Val Ala Lys 100 105 110

Tyr Lys Asn Tyr He Asp Thr He Arg Gin He Val Val Glu Tyr Ser 115 120 125

Asp He Arg Thr Leu Leu Val He Glu Pro Asp Ser Leu Ala Asn Leu 130 135 140

Val Thr Asn Leu Gly Thr Pro Lys Cys Ala Asn Ala Gin Ser Ala Tyr 145 150 155 160

Leu Glu Cys He Asn Tyr Ala Val Thr Gin Leu Asn Leu Pro Asn Val 165 170 175

Ala Met Tyr Leu Asp Ala Gly His Ala Gly Trp Leu Gly Trp Pro Ala 180 185 190

Asn Gin Asp Pro Ala Ala Gin Leu Phe Ala Asn Val Tyr Lys Asn Ala 195 200 205

Ser Ser Pro Arg Ala Leu Arg Gly Leu Ala Thr Asn Val Ala Asn Tyr 210 215 220

Asn Gly Trp Asn He Thr Ser Pro Pro Ser Tyr Thr Gin Gly Asn Ala 225 230 235 240

Val Tyr Asn Glu Lys Leu Tyr He His Ala He Gly Pro Leu Leu Ala 245 250 255

Asn His Gly Trp Ser Asn Ala Phe Phe He Thr Asp Gin Gly Arg Ser 260 265 270

Gly Lys Gin Pro Thr Gly Gin Gin Gin Trp Gly Asp Trp Cys Asn Val 275 280 285

He Gly Thr Gly Phe Gly He Arg Pro Ser Ala Asn Thr Gly Asp Ser 290 295 300

Leu Leu Asp Ser Phe Val Trp Val Lys Pro Gly Gly Glu Cys Asp Gly 305 310 315 320

Thr Ser Asp Ser Ser Ala Pro Arg Phe Asp Ser His Cys Ala Leu Pro 325 330 335

Asp Ala Leu Gin Pro Ala Pro Gin Ala Gly Ala Trp Phe Gin Ala Tyr 340 345 350

Phe Val Gin Leu Leu Thr Asn Ala Asn Pro Ser Phe Leu 355 360 365

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1201 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..704, 775..1201)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CAG CAA CCG GGT ACC AGC ACC CCC GAG GTC CAT CCC AAG TTG ACA ACC 48 Gin Gin Pro Gly Thr Ser Thr Pro Glu Val His Pro Lys Leu Thr Thr 1 5 10 15

TAC AAG TGT ACA AAG TCC GGG GGG TGC GTG GCC CAG GAC ACC TCG GTG 96

Tyr Lys Cys Thr Lys Ser Gly Gly Cys Val Ala Gin Asp Thr Ser Val 20 25 30

GTC CTT GAC TGG AAC TAC CGC TGG ATG CAC GAC GCA AAC TAC AAC TCG 144 Val Leu Asp Trp Asn Tyr Arg Trp Met His Asp Ala Asn Tyr Asn Ser 35 40 45

TGC ACC GTC AAC GGC GGC GTC AAC ACC ACG CTC TGC CCT GAC GAG GCG 192 Cys Thr Val Asn Gly Gly Val Asn Thr Thr Leu Cys Pro Asp Glu Ala 50 55 60

ACC TGT GGC AAG AAC TGC TTC ATC GAG GGC GTC GAC TAC GCC GCC TCG 240 Thr Cys Gly Lys Asn Cys Phe He Glu Gly Val Asp Tyr Ala Ala Ser 65 70 75 80

GGC GTC ACG ACC TCG GGC AGC AGC CTC ACC ATG AAC CAG TAC ATG CCC 288 Gly Val Thr Thr Ser Gly Ser Ser Leu Thr Met Asn Gin Tyr Met Pro 85 90 95

AGC AGC TCT GGC GGC TAC AGC AGC GTC TCT CCT CGG CTG TAT CTC CTG 336 Ser Ser Ser Gly Gly Tyr Ser Ser Val Ser Pro Arg Leu Tyr Leu Leu 100 105 110

GAC TCT GAC GGT GAG TAC GTG ATG CTG AAG CTC AAC GGC CAG GAG CTG 384 Asp Ser Asp Gly Glu Tyr Val Met Leu Lys Leu Asn Gly Gin Glu Leu 115 120 125

AGC TTC GAC GTC GAC CTC TCT GCT CTG CCG TGT GGA GAG AAC GGC TCG 432 Ser Phe Asp Val Asp Leu Ser Ala Leu Pro Cys Gly Glu Asn Gly Ser 130 135 140

CTC TAC CTG TCT CAG ATG GAC GAG AAC GGG GGC GCC AAC CAG TAT AAC 480 Leu Tyr Leu Ser Gin Met Asp Glu Asn Gly Gly Ala Asn Gin Tyr Asn 145 150 155 160

ACG GCC GGT GCC AAC TAC GGG AGC GGC TAC TGC GAT GCT CAG TGC CCC 528 Thr Ala Gly Ala Asn Tyr Gly Ser Gly Tyr Cys Asp Ala Gin Cys Pro 165 170 175

GTC CAG ACA TGG AGG AAC GGC ACC CTC AAC ACT AGC CAC CAG GGC TTC 576 Val Gin Thr Trp Arg Asn Gly Thr Leu Asn Thr Ser His Gin Gly Phe 180 185 190

TGC TGC AAC GAG ATG GAT ATC CTG GAG GGC AAC TCG AGG GCG AAT GCC 624 Cys Cys Asn Glu Met Asp He Leu Glu Gly Asn Ser Arg Ala Asn Ala 195 200 205

TTG ACC CCT CAC TCT TGC ACG GCC ACG GCC TGC GAC TCT GCC GGT TGC 672 Leu Thr Pro His Ser Cys Thr Ala Thr Ala Cys Asp Ser Ala Gly Cys 210 215 220

GGC TTC AAC CCC TAT GGC AGC GGC TAC AAA AG GTGAGCCTGA 714

Gly Phe Asn Pro Tyr Gly Ser Gly Tyr Lys Ser 225 230 235

TGCCACTACT ACCCCTTTCC TGGCGCTCTC GCGGTTTTCC ATGCTGACAT GGTTTTCCAG 774

C TAC TAC GGC CCC GGA GAT ACC GTT GAC ACC TCC AAG ACC TTC ACC 820

Tyr Tyr Gly Pro Gly Asp Thr Val Asp Thr Ser Lys Thr Phe Thr 240 245 250

ATC ATC ACC CAG TTC AAC ACG GAC AAC GGC TCG CCC TCG GGC AAC CTT 868 He He Thr Gin Phe Asn Thr Asp Asn Gly Ser Pro Ser Gly Asn Leu 255 260 265

GTG AGC ATC ACC CGC AAG TAC CAG CAA AAC GGC GTC GAC ATC CCC AGC 916 Val Ser He Thr Arg Lys Tyr Gin Gin Asn Gly Val Asp He Pro Ser 270 275 280

GCC CAG CCC GGC GGC GAC ACC ATC TCG TCC TGC CCG TCC GCC TCA GCC 964 Ala Gin Pro Gly Gly Asp Thr He Ser Ser Cys Pro Ser Ala Ser Ala 285 290 295

TAC GGC GGC CTC GCC ACC ATG GGC AAG GCC CTG AGC AGC GGC ATG GTG 1012 Tyr Gly Gly Leu Ala Thr Met Gly Lys Ala Leu Ser Ser Gly Met Val 300 305 310

CTC GTG TTC AGC ATT TGG AAC GAC AAC AGC CAG TAC ATG AAC TGG CTC 1060 Leu Val Phe Ser He Trp Asn Asp Asn Ser Gin Tyr Met Asn Trp Leu 315 320 325 330

GAC AGC GGC AAC GCC GGC CCC TGC AGC AGC ACC GAG GGC AAC CCA TCC 1108 Asp Ser Gly Asn Ala Gly Pro Cys Ser Ser Thr Glu Gly Asn Pro Ser 335 340 345

AAC ATC CTG GCC AAC AAC CCC AAC ACG CAC GTC GTC TTC TCC AAC ATC 1156

Asn He Leu Ala Asn Asn Pro Asn Thr His Val Val Phe Ser Asn He 350 355 360

CGC TGG GGA GAC ATT GGG TCT ACT ACG AAC TCG ACT GCG CCC CCG 1201

Arg Trp Gly Asp He Gly Ser Thr Thr Asn Ser Thr Ala Pro Pro 365 370 375

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 377 amino acids »

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Gin Gin Pro Gly Thr Ser Thr Pro Glu Val His Pro Lys Leu Thr Thr 1 5 10 15

Tyr Lys Cys Thr Lys Ser Gly Gly Cys Val Ala Gin Asp Thr Ser Val 20 25 30

Val Leu Asp Trp Asn Tyr Arg Trp Met His Asp Ala Asn Tyr Asn Ser 35 40 45

Cys Thr Val Asn Gly Gly Val Asn Thr Thr Leu Cys Pro Asp Glu Ala 50 55 60

Thr Cys Gly Lys Asn Cys Phe He Glu Gly Val Asp Tyr Ala Ala Ser 65 70 75 80

Gly Val Thr Thr Ser Gly Ser Ser Leu Thr Met Asn Gin Tyr Met Pro 85 90 95

Ser Ser Ser Gly Gly Tyr Ser Ser Val Ser Pro Arg Leu Tyr Leu Leu 100 105 110

Asp Ser Asp Gly Glu Tyr Val Met Leu Lys Leu Asn Gly Gin Glu Leu 115 120 125

Ser Phe Asp Val Asp Leu Ser Ala Leu Pro Cys Gly Glu Asn Gly Ser 130 135 140

Leu Tyr Leu Ser Gin Met Asp Glu Asn Gly Gly Ala Asn Gin Tyr Asn 145 150 155 160

Thr Ala Gly Ala Asn Tyr Gly Ser Gly Tyr Cys Asp Ala Gin Cys Pro 165 170 175

Val Gin Thr Trp Arg Asn Gly Thr Leu Asn Thr Ser His Gin Gly Phe 180 185 190

Cys Cys Asn Glu Met Asp He Leu Glu Gly Asn Ser Arg Ala Asn Ala 195 200 205

Leu Thr Pro His Ser Cys Thr Ala Thr Ala Cys Asp Ser Ala Gly Cys 210 215 220

Gly Phe Asn Pro Tyr Gly Ser Gly Tyr- Lys Ser Tyr Tyr Gly Pro Gly 225 230 235 240

Asp Thr Val Asp Thr Ser Lys Thr Phe Thr He He Thr Gin Phe Asn 245 250 255

Thr Asp Asn Gly Ser Pro Ser Gly Asn Leu Val Ser He Thr Arg Lys 260 265 270

Tyr Gin Gin Asn Gly Val Asp He Pro Ser Ala Gin Pro Gly Gly Asp 275 280 285

Thr He Ser Ser Cys Pro Ser Ala Ser Ala Tyr Gly Gly Leu Ala Thr 290 295 300

Met Gly Lys Ala Leu Ser Ser Gly Met Val Leu Val Phe Ser He Trp 305 310 315 320

Asn Asp Asn Ser Gin Tyr Met Asn Trp Leu Asp Ser Gly Asn Ala Gly 325 330 335

Pro Cys Ser Ser Thr Glu Gly Asn Pro Ser Asn He Leu Ala Asn Asn 340 345 350

Pro Asn Thr His Val Val Phe Ser Asn He Arg Trp Gly Asp He Gly 355 360 365

Ser Thr Thr Asn Ser Thr Ala Pro Pro 370 375

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1155 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..56, 231..1155)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGG GTC CGA TTT GCC GGC GTT AAC ATC GCG GGT TTT GAC TTT GGC TGT 48

Gly Val Arg Phe Ala Gly Val Asn He Ala Gly Phe Asp Phe Gly Cys 1 5 10 15

ACC ACA GA GTGAGTACCC TTGTTTCCTG GTGTTGCTGG CTGGTTGGGC 96

Thr Thr Asp

GGGTATACAG CGAAGCGGAC GCAAGAACAC CGCCGGTCCG CCACCATCAA GATGTGGGTG 156

GTAAGCGGCG GTGTTTTGTA CAACTACCTG ACAGCTCACT CAGGAAATGA GAATTAATGG 216

AAGTCTTGTT ACAG T GGC ACT TGC GTT ACC TCG AAG GTT TAT CCT CCG 264

Gly Thr Cys Val Thr Ser Lys Val Tyr Pro Pro 20 25 30

TTG AAG AAC TTC ACC GGC TCA AAC AAC TAC CCC GAT GGC ATC GGC CAG 312 Leu Lys Asn Phe Thr Gly Ser Asn Asn Tyr Pro Asp Gly He Gly Gin 35 40 45

ATG CAG CAC TTC GTC AAC GAG GAC GGG ATG ACT ATT TTC CGC TTA CCT 360 Met Gin His Phe Val Asn Glu Asp Gly Met Thr He Phe Arg Leu Pro 50 55 60

GTC GGA TGG CAG TAC CTC GTC AAC AAC AAT TTG GGC GGC AAT CTT GAT 408 Val Gly Trp Gin Tyr Leu Val Asn Asn Asn Leu Gly Gly Asn Leu Asp 65 70 75

TCC ACG AGC ATT TCC AAG TAT GAT CAG CTT GTT CAG GGG TGC CTG TCT 456 Ser Thr Ser He Ser Lys Tyr Asp Gin Leu Val Gin Gly Cys Leu Ser 80 85 90

CTG GGC GCA TAC TGC ATC GTC GAC ATC CAC AAT TAT GCT CGA TGG AAC 504 Leu Gly Ala Tyr Cys He Val Asp He His Asn Tyr Ala Arg Trp Asn 95 100 105 110

GGT GGG ATC ATT GGT CAG GGC GGC CCT ACT AAT GCT CAA TTC ACG AGC 552 Gly Gly He He Gly Gin Gly Gly Pro Thr Asn Ala Gin Phe Thr Ser 115 120 125

CTT TGG TCG CAG TTG GCA TCA AAG TAC GCA TCT CAG TCG AGG GTG TGG 600 Leu Trp Ser Gin Leu Ala Ser Lys Tyr Ala Ser Gin Ser Arg Val Trp 130 135 140

TTC GGC ATC ATG AAT GAG CCC CAC GAC GTG AAC ATC AAC ACC TGG GCT 648 Phe Gly He Met Asn Glu Pro His Asp Val Asn He Asn Thr Trp Ala 145 150 155

GCC ACG GTC CAA GAG GTT GTA ACC GCA ATC CGC AAC GCT GGT GCT ACG 696 Ala Thr Val Gin Glu Val Val Thr Ala He Arg Asn Ala Gly Ala Thr 160 165 170

TCG CAA TTC ATC TCT TTG CCT GGA AAT GAT TGG CAA TCT GCT GGG GCT 744 Ser Gin Phe He Ser Leu Pro Gly Asn Asp Trp Gin Ser Ala Gly Ala 175 180 185 190

TTC ATA TCC GAT GGC AGT GCA GCC GCC CTG TCT CAA GTC ACG AAC CCG 792 Phe He Ser Asp Gly Ser Ala Ala Ala Leu Ser Gin Val Thr Asn Pro 195 200 205

GAT GGG TCA ACA ACG AAT CTG ATT TTT GAC GTG CAC AAA TAC TTG GAC 840 Asp Gly Ser Thr Thr Asn Leu He Phe Asp Val His Lys Tyr Leu Asp 210 215 220

TCA GAC AAC TCC GGT ACT CAC GCC GAA TGT ACT ACA AAT AAC ATT GAC 888 Ser Asp Asn Ser Gly Thr His Ala Glu Cys Thr Thr Asn Asn He Asp 225 230 235

GGC GCC TTT TCT CCG CTT GCC ACT TGG CTC CGA CAG AAC AAT CGC CAG 936 Gly Ala Phe Ser Pro Leu Ala Thr Trp Leu Arg Gin Asn Asn Arg Gin 240 245 250

GCT ATC CTG ACA GAA ACC GGT GGT GGC AAC GTT CAG TCC TGC ATA CAA 984 Ala He Leu Thr Glu Thr Gly Gly Gly Asn Val Gin Ser Cys He Gin 255 260 265 270

GAC ATG TGC CAG CAA ATC CAA TAT CTC AAC CAG AAC TCA GAT GTC TAT 1032 Asp Met Cys Gin Gin He Gin Tyr Leu Asn Gin Asn Ser Asp Val Tyr 275 280 285

CTT GGC TAT GTT GGT TGG GGT GCC GGA TCA TTT GAT AGC ACG TAT GTC 1080 Leu Gly Tyr Val Gly Trp Gly Ala Gly Ser Phe Asp Ser Thr Tyr Val 290 295 300

CTG ACG GAA ACA CCG ACT AGC AGT GGT AAC TCA TGG ACG GAC ACA TCC 1128 Leu Thr Glu Thr Pro Thr Ser Ser Gly Asn Ser Trp Thr Asp Thr Ser 305 310 315

TTG GTC AGC TCG TGT CTC GCA AGA AAG 1155

Leu Val Ser Ser Cys Leu Ala Arg Lys 320 325

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 327 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Gly Val Arg Phe Ala Gly Val Asn He Ala Gly Phe Asp Phe Gly Cys 1 5 10 15

Thr Thr Asp Gly Thr Cys Val Thr Ser Lys Val Tyr Pro Pro Leu Lys 20 25 30

Asn Phe Thr Gly Ser Asn Asn Tyr Pro Asp Gly He Gly Gin Met Gin 35 40 45

His Phe Val Asn Glu Asp Gly Met Thr He Phe Arg Leu Pro Val Gly 50 55 60

Trp Gin Tyr Leu Val Asn Asn Asn Leu Gly Gly Asn Leu Asp Ser Thr 65 70 75 80

Ser He Ser Lys Tyr Asp Gin Leu Val Gin Gly Cys Leu Ser Leu Gly 85 90 95

Ala Tyr Cys He Val Asp He His Asn Tyr Ala Arg Trp Asn Gly Gly 100 105 110

He He Gly Gin Gly Gly Pro Thr Asn Ala Gin Phe Thr Ser Leu Trp 115 120 125

Ser Gin Leu Ala Ser Lys Tyr Ala Ser Gin Ser Arg Val Trp Phe Gly 130 135 140

He Met Asn Glu Pro His Asp Val Asn He Asn Thr Trp Ala Ala Thr 145 150 155 160

Val Gin Glu Val Val Thr Ala He Arg Asn Ala Gly Ala Thr Ser Gin 165 170 175

Phe He Ser Leu Pro Gly Asn Asp Trp Gin Ser Ala Gly Ala Phe He 180 185 190

Ser Asp Gly Ser Ala Ala Ala Leu Ser Gin Val Thr Asn Pro Asp Gly 195 200 205

Ser Thr Thr Asn Leu He Phe Asp Val His Lys Tyr Leu Asp Ser Asp 210 215 220

Asn Ser Gly Thr His Ala Glu Cys Thr Thr Asn Asn He Asp Gly Ala 225 230 235 240

Phe Ser Pro Leu Ala Thr Trp Leu Arg Gin Asn Asn Arg Gin Ala He 245 250 255

Leu Thr Glu Thr Gly Gly Gly Asn Val Gin Ser Cys He Gin Asp Met 260 265 270

Cys Gin Gin He Gin Tyr Leu Asn Gin Asn Ser Asp Val Tyr Leu Gly 275 280 285

Tyr Val Gly Trp Gly Ala Gly Ser Phe Asp Ser Thr Tyr Val Leu Thr

290 295 300

Glu Thr Pro Thr Ser Ser Gly Asn Ser Trp Thr Asp Thr Ser Leu Val 305 310 315 320

Ser Ser Cys Leu Ala Arg Lys 325

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 72 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..72

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CGT GGC ACC ACC ACC ACC CGC CGC CCA GCC ACT ACC ACT GGA AGC TCT 48 Arg Gly Thr Thr Thr Thr Arg Arg Pro Ala Thr Thr Thr Gly Ser Ser 1 5 10 15

CCC GGA CCT ACC CAG TCT CAC TAC 72

Pro Gly Pro Thr Gin Ser His Tyr 20

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Arg Gly Thr Thr Thr Thr Arg Arg Pro Ala Thr Thr Thr Gly Ser Ser 1 5 10 15

Pro Gly Pro Thr Gin Ser His Tyr 20

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 129 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(i ) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..129

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GGC GCT GCA AGC TCA AGC TCG TCC ACG CGC GCC GCG TCG ACG ACT TCT 48 Gly Ala Ala Ser Ser Ser Ser Ser Thr Arg Ala Ala Ser Thr Thr Ser 1 5 10 15

CGA GTA TCC CCC ACA ACA TCC CGG TCG AGC TCC GCG ACG CCT CCA CCT 96 Arg Val Ser Pro Thr Thr Ser Arg Ser Ser Ser Ala Thr Pro Pro Pro 20 25 30

GGT TCT ACT ACT ACC AGA GTA CCT CCA GTC GGA 129

Gly Ser Thr Thr Thr Arg Val Pro Pro Val Gly 35 40

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Gly Ala Ala Ser Ser Ser Ser Ser Thr Arg Ala Ala Ser Thr Thr Ser 1 5 10 15

Arg Val Ser Pro Thr Thr Ser Arg Ser Ser Ser Ala Thr Pro Pro Pro 20 25 30

Gly Ser Thr Thr Thr Arg Val Pro Pro Val Gly 35 40

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 81 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..81

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCC CCG CCT GCG TCC AGC ACG ACG TTT TCG ACT ACA CCG AGG AGC TCG 48 Pro Pro Pro Ala Ser Ser Thr Thr Phe Ser Thr Thr Pro Arg Ser Ser 1 5 10 15

ACG ACT TCG AGC AGC CCG AGC TGC ACG CAG ACT 81

Thr Thr Ser Ser Ser Pro Ser Cys Thr Gin Thr 20 25

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Pro Pro Pro Ala Ser Ser Thr Thr Phe Ser Thr Thr Pro Arg Ser Ser 1 5 10 15

Thr Thr Ser Ser Ser Pro Ser Cys Thr Gin Thr 20 25

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

( ix) FEATURE :

(A) NAME/KEY: CDS

(B) LOCATION: 1..102

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CCG GGA GCC ACT ACT ATC ACC ACT TCG ACC CGG CCA CCA TCC GGT CCA 48 Pro Gly Ala Thr Thr He Thr Thr Ser Thr Arg Pro Pro Ser Gly Pro 1 5 10 15

ACC ACC ACC ACC AGG GCT ACC TCA ACA AGC TCA TCA ACT CCA CCC ACG 96 Thr Thr Thr Thr Arg Ala Thr Ser Thr Ser Ser Ser Thr Pro Pro Thr 20 25 30

AGC TCT 102

Ser Ser

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Pro Gly Ala Thr Thr He Thr Thr Ser Thr Arg Pro Pro Ser Gly Pro 1 5 10 15

Thr Thr Thr Thr Arg Ala Thr Ser Thr Ser Ser Ser Thr Pro Pro Thr 20 25 30

Ser Ser

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..51

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

ATG TAT CGG AAG TTG GCC GTC ATC TCG GCC TTC TTG GCC ACA GCT CGT 48 Met Tyr Arg Lys Leu Ala Val He Ser Ala Phe Leu Ala Thr Ala Arg 1 5 10 15

GCT 51

Ala

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Met Tyr Arg Lys Leu Ala Val He Ser Ala Phe Leu Ala Thr Ala Are 1 5 10 15

Ala

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 72 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..72

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

ATG ATT GTC GGC ATT CTC ACC ACG CTG GCT ACG CTG GCC ACA CTC GCA 48 Met He Val Gly He Leu Thr Thr Leu Ala Thr Leu Ala Thr Leu Ala 1 5 10 15

GCT AGT GTG CCT CTA GAG GAG CGG 72

Ala Ser Val Pro Leu Glu Glu Arg 20

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Met He Val Gly He Leu Thr Thr Leu Ala Thr Leu Ala Thr Leu Ala 1 5 10 15

Ala Ser Val Pro Leu Glu Glu Arg . .

20

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 66 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1-.66

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

ATG GCG CCC TCA GTT ACA CTG CCG TTG ACC ACG GCC ATC CTG GCC ATT 48 Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala He Leu Ala He 1 5 10 15

GCC CGG CTC GTC GCC GCC 66

Ala Arg Leu Val Ala Ala 20

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( i) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala He Leu Ala He 1 5 10 15

Ala Arg Leu Val Ala Ala 20

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 63 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..63

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

ATG AAC AAG TCC GTG GCT CCA TTG CTG CTT GCA GCG TCC ATA CTA TAT 48 Met Asn Lys Ser Val Ala Pro Leu Leu Leu Ala Ala Ser He Leu Tyr 1 5 10 15

GGC GGC GCC GTC GCA 63

Gly Gly Ala Val Ala 20

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Met Asn Lys Ser Val Ala Pro Leu Leu Leu Ala Ala Ser He Leu Tyr 1 5 10 15

Gly Gly Ala Val Ala 20

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 777 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

AAACCAGCTG TGACCAGTGG GCAACCTTCA CTGGCAACGG CTACACAGTC AGCAACAACC 60

TTTGGGGAGC ATCAGCCGGC TCTGGATTTG GCTGCGTGAC GGCGGTATCG CTCAGCGGCG 120

GGGCCTCCTG GCACGCAGAC TGGCAGTGGT CCGGCGGCCA GAACAACGTC AAGTCGTACC 180

AGAACTCTCA GATTGCCATT CCCCAGAAGA GGACCGTCAA CAGCATCAGC AGCATGCCCA 240

CCACTGCCAG CTGGAGCTAC AGCGGGAGCA ACATCCGCGC TAATGTTGCG TATGACTTGT 300

TCACCGCAGC CAACCCGAAT CATGTCACGT ACTCGGGAGA CTACGAACTC ATGATCTGGT 360

AAGCCATAAG AAGTGACCCT CCTTGATAGT TTCGACTAAC AACATGTCTT GAGGCTTGGC 420

AAATACGGCG ATATTGGGCC GATTGGGTCC TCACAGGGAA CAGTCAACGT CGGTGGCCAG 480

AGCTGGACGC TCTACTATGG CTACAACGGA GCCATGCAAG TCTATTCCTT TGTGGCCCAG 540

ACCAACACTA CCAACTACAG CGGAGATGTC AAGAACTTCT TCAATTATCT CCGAGACAAT 600

AAAGGATACA ACGCTGCAGG CCAATATGTT CTTAGTAAGT CACCCTCACT GTGACTGGGC 660

TGAGTTTGTT GCAACGTTTG CTAACAAAAC CTTCGTATAG GCTACCAATT TGGTACCGAG 720

CCCTTCACGG GCAGTGGAAC TCTGAACGTC GCATCCTGGA CCGCATCTAT CAACTAA 777

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 218 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Gin Thr Ser Cys Asp Gin Trp Ala Thr Phe Thr Gly Asn Gly Tyr Thr 1 5 10 15

Val Ser Asn Asn Leu Trp Gly Ala Ser Ala Gly Ser Gly Phe Gly Cys 20 25 30

Val Thr Ala Val Ser Leu Ser Gly Gly Ala Ser Trp His Ala Asp Trp 35 40 45

Gin Trp Ser Gly Gly Gin Asn Asn Val Lys Ser Tyr Gin Asn Ssr Gin 50 55 60

He Ala He Pro Gin Lys Arg Thr Val Asn Ser He Ser Ser Met Pro 65 70 75 80

Thr Thr Ala Ser Trp Ser Tyr Ser Gly Ser Asn He Arg Ala Asn Val 85 90 95

Ala Tyr Asp Leu Phe Thr Ala Ala Asn Pro Asn His Val Thr Tyr Ser 100 105 110

Gly Asp Tyr Glu Leu Met He Trp Leu Gly Lys Tyr Gly Asp He Gly 115 120 125

Pro He Gly Ser Ser Gin Gly Thr Val Asn Val Gly Gly Gin Ser Trp 130 135 140

Thr Leu Tyr Tyr Gly Tyr Asn Gly Ala Met Gin Val Tyr Ser Phe Val 145 150 155 160

Ala Gin Thr Asn Thr Thr Asn Tyr Ser Gly Asp Val Lys Asn Phe Phe 165 170 175

Asn Tyr Leu Arg Asp Asn Lys Gly Tyr Asn Ala Ala Gly Gin Tyr Val 180 185 190

Leu Ser Tyr Gin Phe Gly Thr Glu Pro Phe Thr Gly Ser Gly Thr Leu 195 200 205

Asn Val Ala Ser Trp Thr Ala Ser He Asn 210 215

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: ATGAAGTTCC TTCAAGTCCT CCCTGCCCTC ATACCGGCCG CCCTGGCC 48

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Met Lys Phe Leu Gin Val Leu Pro Ala Leu He Pro Ala Ala Leu Ala 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: AGCTCGTAGA GCGTTGACTT GCCTGTGGTC TGTCCAGACG GGGGACGATA GAATGCG 57

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: GTCACCTTCT CCAACATCAA GTTCGGACCC ATTGGCAGCA CCGGCTAA 48

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: GGGGTTTAAA CCCGCGGGGA TT 22

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

TGAGCCGAGG CCTCC 15

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: AGCTTGAGAT CTGAAGCT 18

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: GATCGC 6

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: TTATTAGTAA TATGCA 16

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: CTAGAGGAGC GGTCGGGAAC CGCTAC 26

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Leu Glu Glu Arg Ser Gly Thr Ala Thr 1 5

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: AAACCCCGGG TGATTTATTT TTTTTGTATC TACTTCTGA 39

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids »

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

( ii ) MOLECULE TYPE : peptide

(xi ) SEQUENCE DESCRIPTION : SEQ ID NO: 47 :

Lys Pro Arg Val He Tyr Phe Phe Cys He Tyr Phe 1 5 10

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Cys Gly Gly Gin Asn Val Ser Gly Pro Thr Cys Cys Ala Ser Gly Ser 1 5 10 15

Thr Cys